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                                             ABSTRACT  
Background 
Acute Heart Failure (AHF) is a well recognised growing healthcare problem with increasing 
hospitalisation rate, high mortality and severe financial burden on healthcare budget. Mitral 
regurgitation (MR) is known as a highly prevalent valvular disease with an impact on prognosis in 
AHF not clearly established. 
Aims 
The aim of Mitral regurgitation and Heart Failure (MRAHF) program was to assess the prognostic 
impact of mitral regurgitation (MR) in patients admitted with acute heart failure (HF) or 
exacerbation of chronic HF in a single center prospective cross-sectional study, to assess the 
significance of financial burden of admitted HF patients and to look at how many of these patients 
were managed according to NICE recommendations. 
Methods 
All patients admitted to a district general hospital with symptoms of AHF over a period of 1 year 
were included. Patients with raised bedside point-of-care BNP (Brain Natriuretic Peptide) had 
standard clinical assessment and transthoracic echocardiography within 48 hour of recruitment. 
Echocardiography included quantitative assessment of MR, assessment of cardiac chambers and 
other valvular function. MR was categorised as mild, moderate, moderate to severe and severe. MR 
of moderate severity and above was considered significant. Demographic and comorbidity data 
including known history of MR, 6 months and 1 year mortality were documented. All MRAHF 
patients` clinical management pathway has been reviewed with comparison to the NICE guideline, 
and their outcome were recorded as well. 
Results 
418 patients were included into the study. All patients (100%) were found to have MR; 165 (39.5%) 
had significant MR. Those with significant MR had features of left ventricular (LV) remodelling with 
increase in end-diastolic (LVEDV) (129±58 ml vs 99±49 ml, p<0.0001) and end systolic (LVESV) 
(82±50ml v s 58±41ml, p<0.0001) volumes and reduction in LV ejection fraction (LVEF) (38±14% vs 
45±14%, p<0.0001) in presence of significant volume overload (MR RV 47.8±17.7cm3 vs 
17.8±7.0cm3, P<0.0001). Severity of pulmonary hypertension (PHT) and right ventricular (RV) 
dysfunction were also significantly worse in presence of significant MR: systolic pulmonary artery 
pressures (SPAP) (57±17.9mmHg vs 49.7±18mmHg, p<0.0001), RV fractional area change (RVFAC) 
(34.1±12% vs 38.8±12%, p<0.0001). In presence of significant MR there was significant increase in 6-
month mortality (34.9% vs 23.8% p<0.05). 232 (55.5%) patients from the whole cohort did not follow 
the NICE guidelines and most of them had isolated RVSD, significant MR and twice higher mortality. 
219 MRAHF patients (52%) had missed diagnosis of HF by coding team. The rest of MRAHF patients 






Significant MR is associated with adverse changes in LV geometry, prominent PHT and LV/RV 
dysfunction and a reduced survival in AHF. Patients with significant MR had a more impaired RV 
function and prominent PAP then the other group. The majority of HF patients whose management 
was not based on the NICE guidelines had an adverse outcome. The cost of MRAHF patients with 
significant RV dysfunction was higher compared to others. The use of bedside BNP test has 
demonstrated high effectiveness in triaging of HF patients. 
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CHAPTER 1. INTRODUCTION  
1.1.1 Background 
In recent years, heart failure (HF) has been recognised as a major and increasing public health 
problem (1-3) on an epidemic scale (4). From 20 million people being affected by HF in 2008(5) ;  this 
figure has grown up to 37.7 million worldwide (3). The incidence of HF hospitalisations has tripled 
over the last 3 decades (6-8). In Europe, about 5% of all acute hospital admissions are HF related 
(9,10). It is estimated that HF accounted for 1.2% of National Health Service (NHS) expenditure in the 
United Kingdom (UK) (11)  and similar in other countries (12-15). After discharge, HF patients are at 
high risk of rehospitalisation or death. 3-month mortality and readmissions are close to 14 and 25% 
respectively (16). Complex pharmacotherapy, community care, and particularly frequent hospital 
admissions (17,18) have significant cumulative effect on health economics.   
The multifactorial nature of HF makes it difficult to elucidate any single haemodynamic risk factor for 
recurrent hospital admissions (19). Approximately half of hospitalised HF patients have moderate to 
severely reduced left ventricular (LV) systolic function, with an ejection fraction (LVEF) of < 40 % 
(20). It is not clear if changes in LV geometry and mitral valve apparatus could play an additional role 
in the course of disease. The devastating effect of ischaemic mitral regurgitation (MR) on patient 
survival (21) might be secondary to the change of myocardial shape. In general, development of 
significant MR is strongly associated with worsened prognosis in patients with HF, regardless of its 
aetiology (22). 
1.1.2 History of Heart failure 
Descriptions of heart failure exist from ancient Egypt, Greece, and India, and the Romans were 
known to use the foxglove as medicine. There was little understanding of the nature of the condition  
until William Harvey described the circulation in 1628 (23). Röntgen's discovery of X-rays and 
Einthoven's development of electrocardiography in the 1890s led to improvements in the 
investigation of heart failure. The advent of echocardiography, cardiac catheterisation, and nuclear 
medicine have since improved the diagnosis and investigation of patients with heart failure (23). 
Blood letting and leeches were used for centuries, and William Withering published his account of 
the benefits of digitalis in 1785. In the 19th and early 20th centuries, heart failure associated with 
fluid retention was treated with Southey's tubes, which were inserted into oedematous peripheries, 
allowing some drainage of fluid (23).   
It was not until the 20th century that diuretics were developed. The early, mercurial agents, 
however, were associated with substantial toxicity, unlike the thiazide diuretics, which were 
introduced in the 1950s (23). Vasodilators were not widely used until the development of 
angiotensin converting enzyme inhibitors in the 1970s. The landmark CONSENSUS-I study (first 
cooperative north Scandinavian enalapril survival study), published in 1987, showed the unequivocal 




FIGURE 1. Proportion of the population living with heart failure in individual countries across the globe (24-27). Estimates based on 
a single centre or hospital are indicated by an H. No population‐based studies have reportedly been conducted to estimate the 
proportion of the population living with heart failure in Africa (28) or Latin America (29). 
 
 
1.1.3 The global burden of Heart failure 
In many countries, population‐based studies have found that about 1–2% of people have heart 
failure, and similar or higher proportions have been reported in single‐centre studies (FIGURE 1)(24-
29). Heart failure becomes more common with increasing age. In North America and Europe, few 
patients with heart failure are 50 years of age or younger (30-32) and more than 80% are 65 years of 
age or older (33). The number of patients with heart failure is predicted to increase in countries with 
ageing populations (34). Japan, in particular, has the most rapidly ageing population of all 
economically developed nations (35). In the USA, there were 5.8 million patients living with heart 
failure in 2012, and this is expected to rise to 8.5 million by 2030 (36). Another contributing factor to 
these increasing numbers is the improvement in treating heart attacks and other cardiovascular 
diseases that damage or place an extra burden on the heart. More patients with these conditions 
are surviving now than did in the past, but those who survive are at high risk of going on to develop 
heart failure (37). 
In economically developing areas, such as parts of Latin America and Asia, the numbers of patients 
with heart failure are also increasing (24,38,39). The increase is largely a result of the shift towards a 
Western‐type lifestyle and its associated diseases, for example, conditions such as diabetes increase 
the risk of developing heart failure. 
Infections remain a common cause of heart failure in many parts of the world and can strike at any 
age. Heart failure is not a disease of the elderly in sub‐Saharan Africa, where half of patients 
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hospitalized with the disease are 55 years of age or younger (40). Patients in the Asia Pacific region 
also tend to be younger than those in Western regions (41). Rheumatic fever due to preventable 
bacterial infections is a prominent cause of heart failure in Africa, Asia, Australasia and Latin America 
(24). HIV infection is also a major contributor to heart‐related disease across the world (24). In areas 
of Latin America where Chagas disease is common, nearly half of all heart failure cases are a direct 
result of this preventable parasitic infection (39).  
1.1.4 Heart failure in different ethnic groups 
There is a higher risk of HF incidence among African Americans, which is related to differences in the 
prevalence of hypertension and diabetes mellitus as well as socioeconomic status (42).The 
mechanisms of HF differ by ethnicity as well; interim myocardial infarction has the least influence 
among African Americans, and left ventricular mass increase has the greatest effect among Hispanic 
and white participants (42). 
Although ethnicity has been suggested as an independent risk factor for congestive HF (43,44), the 
direct effect of ethnicity on incidence of congestive HF has not been demonstrated in a population-
based study. Most of the data regarding the incidence of congestive HF are derived from white 
populations, and, therefore, it is not easy to determine the incidence of congestive HF among other 
ethnic groups. Previous studies have shown high mortality and hospitalisation rates due to 
congestive HF among African American compared with white populations (45,46), but did not 
elucidate the factors that induce the onset of congestive HF in a multi-ethnic population. 
Discrepancies in the prevalence and consequences of congestive HF between African Americans and 
whites have been attributed to racial/ethnic differences in the prevalence of coexisting conditions 
such as hypertension and diabetes mellitus, the quality and availability of medical care, and 
disparities in socioeconomic factors (46,47). 
1.1.5 Acute heart failure and rate of hospitalisation 
There are over 67,000 admissions in England with acute heart failure (AHF) each year (48).  Most 
patients admitted to the hospital with AHF have a worsening of chronic HF (CHF), 15- 20% of acute 
HF hospitalisations represent new diagnoses of HF (49). Patients with a new diagnosis of HF are 
much more likely to present with pulmonary oedema or cardiogenic shock, while decompensation of 
chronic HF usually presents with other signs of congestion and fluid retention, such as weight gain, 
exertional dyspnoea, or orthopnoea. These symptoms can begin days or weeks before presentation 
(50).  Hospitalisations for decompensated HF is a powerful predictor of readmissions and post-
discharge death in patients with chronic heart failure (CHF), with mortality as high as 20% after 
discharge (51,52).  
The pattern of hospital admissions has changed dramatically. In the early 1990s only 0.2% of the UK 
population were hospitalised for HF per annum, but the length of stay (LOS) was significantly long; 
mean LOS for a HF related admission was 11.4 days on acute medical wards and 28.5 days on  
geriatric wards. Currently such admissions accounted for more than 5% of adult general medicine 
and geriatric hospital admissions—outnumbering those associated with acute myocardial infarction 
(53). Despite significant reduction of LOS many patients require readmission (54). Within the UK 
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about one third of patients are readmitted within 12 months of discharge, with similar rate reported  
in the USA (53,55). HF readmission rates are higher than the other major causes of hospitalisation 
such as stroke, hip fracture, and respiratory disease. Additionally, patients tend to lose their home 
independence during HF admissions (54). 
1.1.6 Precipitants for heart failure hospitalisations 
The most common known precipitants for HF hospitalisation are noncompliance with medications or 
dietary restrictions, uncontrolled hypertension, ischaemia, arrhythmias, and exacerbation of chronic 
obstructive pulmonary disease with or without pneumonia (56). Other contributors include 
noncardiac conditions such as renal dysfunction, diabetes mellitus, anaemia, and the side effects of 
medications (57). Despite this up to 40-50% of acute decompensated HF episodes have no known 
cause (58). It is imperative that these precipitants, when identified, be defined and treated and that 
effective interventions be developed to prevent recurrence. Euro HF II survey reported high 
incidence of valvular heart disease especially MR in 80% of patients, which was reported on 
echocardiography (59), but no prospective studies are available looking into this matter.  
1.2.1 Definition of heart failure 
HF is a complex clinical syndrome that results from any structural or functional impairment of 
ventricular filling or ejection of blood (60). This is a condition in which the heart does not pump 
enough blood to meet all the needs of the body. Acute heart failure can present as new‑onset heart 
failure in people without known cardiac dysfunction, or as acute decompensation of chronic heart 
failure.  
1.2.2 Asymptomatic heart failure 
The current definition of HF restricts itself to stages at which clinical symptoms are apparent. Before 
clinical symptoms become apparent, patients can present with asymptomatic structural or 
functional cardiac abnormalities [systolic or diastolic left ventricular (LV) dysfunction], which are 
precursors of HF. Recognition of these precursors is important because they are related to poor 
outcomes, and starting treatment at the precursor stage may reduce mortality in patients with 
asymptomatic systolic LV dysfunction (61,62). 
1.2.3 Heart failure as a result of multiple disorders 
The clinical syndrome of HF may result from disorders of the pericardium, myocardium, 
endocardium, heart valves, great vessels or from certain metabolic abnormalities, but most patients 
with HF have symptoms due to impaired left ventricular (LV) myocardial function. HF may be 
associated with a wide spectrum of LV functional abnormalities, which may range from patients with 
normal LV size and preserved ejection fraction (EF) to those with severe dilatation and/or markedly 
reduced EF. In most patients, abnormalities of systolic and diastolic dysfunction coexist. EF is 
considered important in classification of patients with HF because of differing patient demographics, 
comorbid conditions, prognosis, and response to therapies (63) and because most clinical trials 
select patients based on EF. EF values are dependent on the imaging technique used, method of 




The diagnosis of heart failure was traditionally made at the bedside based on clinical evaluation that 
combined characteristic symptoms from the history with various signs on physical examination. 
Other than the obvious need to determine whether a patient has heart failure, it is also important to 
determine what type of heart failure is present. Patients with heart failure need a comprehensive 
workup that begins with the history and physical examination (64). 
1.3.1 Symptoms and signs 
The cardinal manifestations of HF are dyspnoea and fatigue, which may limit exercise tolerance, and 
fluid retention, which may lead to pulmonary and/or splanchnic congestion and/or peripheral 
oedema. Some patients have exercise intolerance but little evidence of fluid retention, whereas 
others complain primarily of oedema, dyspnoea, or fatigue. Because some patients present without 
signs or symptoms of volume overload, the term “heart failure” is preferred over “congestive heart 
failure.” (60) There is no single diagnostic test for HF because it is largely a clinical diagnosis based on 
a careful history and physical examination. TABLE 1 demonstrates more detailed symptomatic 
presentation of heart failure with many of them being non-specific. 




1.3.2 Clinical classifications 
Several classification schemes have been developed for acute HF. Patients are generally divided into 
those who present with HF for the first time and those whose chronic HF worsens. Of the 
approximately 80% of acute HF patients with worsening of chronic HF, less than 10% have advanced 
HF (49). The characteristics of advanced HF include low blood pressure, renal impairment, and signs 
or symptoms of HF that are refractory to standard therapy. 
1.3.2.1 New York Heart Association (NYHA) classification (66) 
This symptom-based scale classifies heart failure in four categories. In Class I heart failure, patients 
do not have any symptoms, there is no limitation of physical activity and they are able to perform 
ordinary physical activity. In Class II heart failure, there is slight limitation of physical activity. 
Patients are comfortable at rest, but ordinary physical activity results in symptoms of HF. With Class 
III, there is marked limitation of physical activity. Patients are comfortable at rest, but less than 
ordinary activity causes symptoms of HF. Class IV is the most severe, when patients are unable to 
carry on any physical activity without symptoms of HF, or symptoms of HF at rest. 
1.3.2.2 Heart failure classification on clinical and haemodynamic 
characteristics 
The European Society of Cardiology guidelines for the diagnosis and treatment of acute HF classifies 
patients into 1 of 6 groups on the basis of typical clinical and hemodynamic characteristics (67), 
based on the work of Cotter (68), Gheorghiade, and colleagues. The first 3 categories of patients 
(those with acute decompensated heart failure [ADHF], hypertensive acute heart failure [AHF], and 
AHF with pulmonary oedema) comprise over 90% of AHF presentations. The patient with ADHF 
typically presents with mild-to-moderate signs and symptoms of congestion and does not meet the 
criteria for other categories. Hypertensive AHF patients are characterized by their relatively 
preserved LV systolic function (LVEF > 40%), elevated blood pressure, and pulmonary oedema. The 
3rd group, patients who have AHF with pulmonary oedema, has a clinical presentation that is 
dominated by severe respiratory distress, orthopnoea, signs of pulmonary oedema (verified by rales 
on physical examination and chest radiography), and hypoxemia (the oxygen saturation is usually 
<90% on room air). 
Patients with low-output syndrome have evidence of tissue hypoperfusion due to HF and display a 
continuum of severity ranging from a low-output state to cardiogenic shock. High-output failure  
presents with warm extremities, pulmonary congestion, and at times low blood pressure (that is, 
sepsis) with high cardiac output and usually an elevated heart rate. Underlying conditions associated 
with this type of ADHF include anaemia, thyrotoxicosis, and Paget’s disease. Right-sided AHF occurs 
most commonly in patients with underlying lung disease, such as those who have chronic 
obstructive pulmonary disease and develop cor pulmonale, or those who have pulmonary 
hypertension for other reasons, including left-heart failure. Right-sided AHF patients generally 




1.3.2.3 Heart failure with preserved, mid-range and reduced ejection fraction  
The main terminology used to describe HF is historical and is based on measurement of the LV 
ejection fraction (EF). EF is considered important in classification of patients with HF because of 
differing patient demographics, comorbid conditions, prognosis, and response to therapies (69) and 
because most clinical trials selected patients based on EF. HF comprises a wide range of patients, 
from those with normal LVEF [typically considered as ≥50%; also referred to as diastolic HF, HF with 
preserved EF (HFpEF)] to those with reduced LVEF [typically considered as < 40%; also referred to as 
systolic HF, HF with reduced EF (HFrEF)] (TABLE 2). Patients with an LVEF in the range of 40–49% 
represent a ‘grey area’, which we now define as HFmrEF (TABLE 2)(19). Differentiation of patients 
with HF based on LVEF is important due to different underlying aetiologies, demographics, co-
morbidities and response to therapies(70). 
 
TABLE 2. Definition of heart failure with preserved (HFpEF), mid-range (HFmrEF) and reduced ejection fraction (HFrEF) 
Type of HF HFrEF HfmrEF HFpEF 
CRITERIA 1 Symptoms ± signs¹ Symptoms ± signs¹ Symptoms ± signs¹ 
2 LVEF < 40% LVEF 40-49% LVEF ≥ 50% 
3 __________ 1. Elevated levels of 
natriuretic peptides2. 
2. At least one additional 
criterion:  
   a. relevant structural 
heart disease (LVH 
and/or LAE).        
   b. diastolic dysfunction. 
1. Elevated levels of 
natriuretic peptides2. 
2. At least one additional 
criterion:  
   a. relevant structural 
heart disease (LVH 
and/or LAE).        
   b. diastolic dysfunction. 
BNP = B-type natriuretic peptide; HF = heart failure; HFmrEF = heart failure with mid-range ejection fraction; HFpEF= heart failure with 
preserved ejection fraction; HFrEF= heart failure with reduced ejection fraction; LAE = left atrial enlargement; LVEF = left ventricular 
ejection fraction; LVH = left ventricular hypertrophy; NT-proBNP = N-terminal pro-B type natriuretic peptide.                                              
¹Signs may not be present in the early stages of HF (especially in HFpEF) and in patients treated with diuretics                                            
2BNP >35 pg/ml and/or NT-proBNP>125 pg/ml. (19) 
1.3.2.4 Congestion and hypoperfusion profiles of heart failure 
Another clinically relevant and widely used system for classifying ADHF was developed by Stevenson 
and colleagues (71). In contrast with the European Society of Cardiology system, this system focuses 
more on the severity of disease at presentation than on the cause of HF. It classifies patients on the 
basis of the clinical presence or absence of hypoperfusion (cold vs warm) and of congestion at rest 
(wet vs dry) (FIGURE 2). Patients with clinical profile A (warm and dry) had a 6-month mortality rate 
of 11%, compared with 40% for profile C (cold and wet), which shows that these clinical profiles can 




FIGURE 2. Hemodynamic profiles of patients presenting with advanced heart failure.  
Modified from: Nohria A, Mielniczuk LM, Stevenson LW. Evaluation and monitoring of patients with acute heart failure syndromes. Am J 
Cardiol 2005;96(6A):32G-40G. 
 
1.4. Diagnostic tests in patients with suspected heart failure 
There are many tests for diagnosis of heart failure (table 3), however echocardiography (ECHO) and 
electrocardiography (ECG) are the most useful in patients with suspected HF. 
 
1.4.1 Transthoracic echocardiography  
Echocardiography provides immediate information on chamber volumes, ventricular systolic and 
diastolic function, wall thickness, and valve function (72-75). This information is crucial in 
determining appropriate treatment (e.g. an ACE inhibitor and beta-blocker for systolic dysfunction or 
surgery for aortic stenosis). Echocardiography is the method of choice in patients with suspected HF, 
for reasons of accuracy, availability (including portability), safety and cost (76-78). 
1.4.1.1 Assessment of left ventricular systolic function 
For the assessment of left ventricular systolic function the main characteristic is ejection fraction, 
which is measured by the modified biplane Simpson`s method. LV end diastolic volume (LVEDV) and 
LV end systolic volume (LVESV) are obtained from apical four- and two-chamber views. This method 
relies on accurate tracing of endocardial borders. In case of poor image quality, contrast agents 
should be used to improve endocardial delineation (78). Tissue Doppler parameters (S wave) and 
deformation imaging techniques (strain and strain rate) have been shown to detect subtle 
abnormalities in systolic function in the preclinical stage; however, measurements may vary among 





1.4.1.2 Assessment of left ventricular diastolic function 
LV diastolic dysfunction is thought to be the underlying pathophysiological abnormality in patients 
with HFpEF and perhaps HFmrEF, and thus its assessment plays an important role in diagnosis. 
Although echocardiography is at present the only imaging technique that can allow for the diagnosis 
of diastolic dysfunction, no single echocardiography variable is sufficiently accurate to be used in 
isolation to make a diagnosis of LV diastolic dysfunction (19). 
1.4.1.3 Assessment of right ventricular function and pulmonary arterial 
pressure 
An obligatory element of echocardiography examination is the assessment of right ventricle (RV) 
structure and function, including RV and right atrial (RA) dimensions, an estimation of RV systolic 
function and pulmonary arterial pressure. Among parameters reflecting RV systolic function, the 
following measures are of particular importance: tricuspid annular plane systolic excursion (TAPSE; 
abnormal TAPSE < 17 mm indicates RV systolic dysfunction) and tissue Doppler-derived tricuspid 
lateral annular systolic velocity (s′) (s′ velocity <9.5 cm/s indicates RV systolic dysfunction) (79,80). 
Systolic pulmonary artery pressure is derived from an optimal recording of maximal tricuspid 
regurgitant jet and the tricuspid systolic gradient, together with an estimate of RA pressure on the 
basis of inferior vena cava (IVC) size and its breathing-related collapse (81). Three-dimensional 
speckle tracking echocardiography may be an additional quantitative method to assess RV function 
(82). 
1.4.2 Electrocardiography 
An abnormal ECG increases the likelihood of the diagnosis of HF, but has low specificity (83-86). 
Some abnormalities on the ECG provide information on aetiology (e.g. myocardial infarction), and 
findings on the ECG might provide indications for therapy (e.g. anticoagulation for AF, pacing for 
bradycardia, CRT if broadened QRS complex). HF is very unlikely (likelihood <2%) in patients 
presenting acutely and with a completely normal ECG (87-89). 
The information provided by these two tests will permit an initial working diagnosis and treatment 
plan in the majority of patients (90). Routine biochemical and haematological investigations are also 
important, partly to determine whether renin–angiotensin–aldosterone blockade can be initiated 
safely (renal function and potassium) and to exclude anaemia (which can mimic or aggravate HF) and 









TABLE 3. Recommendations for the diagnostic investigations for suspected heart failure by European Society of 
Cardiology (65) 
 
BNP = B-type natriuretic peptide; CAD = coronary artery disease; CMR = cardiac magnetic resonance; COPD = chronic obstructive 
pulmonary disease; ECG = electrocardiogram; HF = heart failure; LV = left ventricular; LVEF = left ventricular ejection fraction; MR-proANP 
= mid-regional pro atrial natriuretic peptide; NT-proBNP = N-terminal pro B-type natriuretic peptide; PET = positron emission tomography; 
SPECT = single photon emission computed tomography; TIBC = total iron-binding capacity. 
ᵅ Class of recommendation. 
ᵇ Level of evidence.                                                                                                                                 
ᶜ Additional investigations may be indicated in patients with suspected acute HF in the emergency department/hospital, including 
troponins and D-dimer measurement and right heart catheterization. 
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1.4.3 Natriuretic peptides 
An alternative approach to diagnosis is to measure the blood concentration of a natriuretic peptide, 
which is increased due to a diseased heart or if the load on any chamber is increased (e.g. by AF, 
pulmonary embolism, and some non-cardiovascular conditions, including renal failure)(91-94). A 
normal natriuretic peptide level in an untreated patient virtually excludes significant cardiac disease, 
making an echocardiogram unnecessary. The upper limit of normal in the non-acute setting for B-
type natriuretic peptide (BNP) is 35 pg/mL and for N-terminal pro-BNP (NT-proBNP) it is 125 pg/mL 
(19). For patients presenting with acute onset or worsening of symptoms, the optimal exclusion cut-
off point is 300 pg/mL for NT-proBNP and 100 pg/mL for BNP (95). 
1.4.4 Chest X-ray 
The chest X-ray (CXR) is mainly used to show pulmonary venous congestion or oedema in a patient 
with HF, and is more helpful in the acute setting than in the non-acute setting (86,96). It is important 
to note that significant LV dysfunction may be present without cardiomegaly on the chest X-ray 
(86,96). Otherwise, CXR is of limited use except to identify some alternative cause of patients 
symptoms. 
1.4.5 Routine blood test 
Laboratory testing may reveal the presence of disorders or conditions that can lead to or exacerbate 
HF. The initial evaluation of patients with HF should include a complete blood count, urinalysis, 
serum electrolytes (including calcium and magnesium), glycohemoglobin, and blood lipids, as well as 
tests of both renal and hepatic function. Thyroid function tests (especially thyroid-stimulating 
hormone) should be measured, because both hyperthyroidism and hypothyroidism can be a primary 
or contributory cause of HF. A fasting transferrin saturation is useful to screen for hemochromatosis 
(97). 
 
1.4.6 The role of cardiac imaging in diagnosis of heart failure 
Cardiac imaging plays a central role in the diagnosis of HF and in guiding treatment. Apart from 
echocardiography, which is the one of the main methods for HF diagnosis, there are other modalities 
which are chosen depending on their ability to answer a specific clinical question or 
contraindications and risks of specific tests (78,98).  
1.4.6.1 Cardiac magnetic resonance  
Cardiac magnetic resonance (CMR) is acknowledged as the gold standard for the measurements of 
volumes, mass and EF of both the left and right ventricles, especially in for patients with 




1.4.6.2 Stress echocardiography 
Exercise or pharmacological stress echocardiography may be used for the assessment of inducible 
ischaemia and/or myocardium viability (102) and in some clinical scenarios of patients with valve 
disease (e.g. dynamic mitral regurgitation, low-flow–low-gradient aortic stenosis) (102,103). 
1.4.6.3 Coronary angiography 
Coronary angiography is recommended in patients with HF who suffer from angina pectoris 
recalcitrant to medical therapy (104), provided the patient is otherwise suitable for coronary 
revascularization. Coronary angiography is also recommended in patients with a history of 
symptomatic ventricular arrhythmia or aborted cardiac arrest. Coronary angiography should be 
considered in patients with HF and intermediate to high pre-test probability of CAD and the 
presence of ischaemia in non-invasive stress tests in order to establish the ischaemic aetiology and 
CAD severity (105-107). 
1.5. Heart failure with preserved ejection fraction 
In developed countries, at least 38–54% of patients with heart failure show preserved left ventricular  
ejection fraction. The prevalence of heart failure with preserved ejection fraction is steadily 
increasing and its prognosis is poor (108). It shares a 90-day mortality and readmission rate similar to 
heart failure with reduced ejection fraction. Whereas hospitalisation for patients with heart failure 
with reduced ejection fraction (HFrEF) has declined over the past few years, that of patients with 
HFpEF is on the rise and requires longer lengths of stay (109). 
Although patients with HFpEF have a lower 30-day hospital readmission rate compared with patients 
with HFrEF (25% vs 64%, respectively), no difference is observed in 30-day and 1-year all-cause 
mortality rates (Table 4) (110). Although women have a higher prevalence of HFpEF, the risk of 
death is much greater in men regardless of whether they have preserved or reduced ejection 
fraction (111). Thirty percent of patients with HFpEF die of noncardiac causes compared with 17% of 
patients with systolic heart failure. This comparison emphasizes the role of comorbidities in 
mortality rates (112). 
1.5.1. Pathophysiology of heart failure with preserved ejection fraction 
The pathophysiological process of HFpEF is incompletely understood. Although an abnormality in LV 
relaxation corresponds to diastolic dysfunction, HFpEF is more complex than that, and the 
pathophysiological mechanisms are the subject of vigorous study. Paulus and Tschope (113) have 
proposed a new paradigm that suggests that comorbidities such as obesity, diabetes mellitus, and 
chronic obstructive pulmonary disease lead to a systemic proinflammatory state that induces 
coronary microvascular endothelial inflammation. This inflammation and resultant oxidative stress 
cause stiff cardiomyocytes and interstitial fibrosis, which characterize the myocardial dysfunction 





Arrows in the TABLE 4 indicate increased or decreased prevalence of comorbidities in the given group of HF 
TABLE 4:  
 
1.5.2 Diagnosis of heart failure with preserved ejection fraction 
The diagnosis of HFpEF remains challenging. LVEF is normal and signs and symptoms for HF (TABLE 
1) are often non-specific and do not discriminate well between HF and other clinical conditions. The 
diagnosis of chronic HFpEF, especially in the typical elderly patient with co-morbidities and no 
obvious signs of central fluid overload, is cumbersome. To improve the specificity of diagnosing 
HFpEF, the clinical diagnosis needs to be supported by objective measures of cardiac dysfunction at 
rest or during exercise. The diagnosis of HFpEF requires the following conditions to be fulfilled (see 
TABLE 2) (19): 
• The presence of symptoms and/or signs of HF (see TABLE 1) 
• A ‘preserved’ EF (defined as LVEF ≥50% or 40–49% for HFmrEF) 
• Elevated levels of NPs (BNP > 35 pg/mL and/or NT-proBNP > 125 pg/mL) 
• Objective evidence of other cardiac functional and structural alterations underlying HF  
• In case of uncertainty, a stress test or invasively measured elevated LV filling pressure may be     





FIGURE 3. Step-by-step diagnosis of heart failure with preserved ejection fraction (HFpEF) (108,113). Shortness of breath without 
objective signs of pulmonary congestion is a common early symptom of HFpEF. Interpreting this symptom is especially challenging in 
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elderly patients. Signs or symptoms of heart failure (HF) is the first obligatory criterion in the diagnosis of HFpEF. A nondilated left ventricle 
(LV) with preserved ejection fraction (EF) is the second required criterion for the diagnosis of HFpEF. Presence of echocardiographic 
evidence of diastolic dysfunction with both LV relaxation and filling abnormalities is the third required criterion. Abnormal LV relaxation 
can be a silent echocardiographic finding, whereas abnormal LV filling is associated with symptoms of HF.                                                   
Abbreviations: A, late mitral valve blood flow Doppler velocity; e’, early mitral valve tissue Doppler lengthening velocity; E, early mitral 
valve blood flow Doppler velocity; BNP, brain natriuretic peptide (112). 
The standard approach is to start with the medical history, physical examination, 
electrocardiography, and chest radiography. If heart failure is suspected, 2-dimensional Doppler 
echocardiography is the next step. A 2014 article (108) updated the 2007 European Society of 
Cardiology guideline in terms of evidence for diastolic dysfunction while maintaining the clinical 
orientation of the original approach. The decision tree starts with a measure of the relaxation 
velocity of the LV in early diastole (a tissue Doppler recording of the velocity of the LV at the mitral 
annulus, abbreviated to e’) and asks if LV diastolic dysfunction is present. If not, other considerations 
would be raised, such as primary mitral valve regurgitation, constrictive pericarditis, dyspnoea as an 
anginal equivalent, and noncardiac dyspnoea.  
The stepwise approach then moves to a measure of LV filling pressure (the tissue Doppler index, 
which is the ratio of the mitral early diastolic blood flow velocity to the mitral annular relaxation 
velocity, abbreviated to E/e’). If this criterion is fulfilled, the diagnosis is established. A small number 
of patients will meet these 2 criteria. If these parameters are borderline or the filling pressure is not 
elevated, the next step is to assess other Doppler/echocardiographic parameters and clinical 
features, such as response to exercise, pulmonary arterial pressure, left atrial size (expressed as left 
atrial volume index), brain natriuretic peptide (BNP) levels, and the presence of atrial fibrillation 
(Figure 3). If 2 or more of these additional findings are met, the diagnosis of HFpEF is established. If 
none is present, the diagnosis is excluded (112). 
1.6. Criteria for hospitalisation 
Any patient with ADHF who has hypotension, worsening renal function, or altered mental status 
should be considered high risk and hospitalised. In addition, ADHF patients who present with 
dyspnoea, tachypnoea, or hypoxaemia (again, oxygen saturation of <90%) at rest, or with any 
hemodynamically significant arrhythmia, including atrial fibrillation with rapid ventricular response, 
warrant hospital admission— as does any patient who presents with evidence of an acute coronary 
syndrome (114). Hospitalisation should also be considered for HF patients with any of the following: 
severe weight gain, defined as >5 kg; signs and symptoms of pulmonary or systemic congestion; 
major electrolyte disturbances; repeated implantable cardioverter-defibrillator firings; or 
pneumonia. Furthermore, the clinician should be aware that a patient with ADHF has a poor 
systemic reserve for coping with other medical conditions. 
1.7.1 Treatment of heart failure with reduced ejection fraction (HFrEF) 
1.7.1.1 Angiotensin-converting enzyme inhibitors (ACEI) 
ACEIs have been shown to reduce mortality and morbidity in patients with heart failure with 
reduced ejection fraction (HFrEF) (62,115-118) and are recommended unless contraindicated or not 
tolerated in all symptomatic patients. There is evidence that in clinical practice the majority of 
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patients receive suboptimal doses of ACEI (119). ACEIs are also recommended in patients with 
asymptomatic LV systolic dysfunction, with a recent or remote history of myocardial infarction (MI) 
or acute coronary syndrome (ACS), to reduce the risk of HF development, HF hospitalisation and 
death (60,120). 
1.7.1.2 Beta-blockers 
Beta blockers should be used in all patients with a reduced EF to prevent symptomatic HF, even if 
they do not have a history of MI (60,121). Beta-blockers reduce mortality and morbidity in 
symptomatic patients with HFrEF, despite treatment with an ACEI and, in most cases, a diuretic (122-
126), but have not been tested in congested or decompensated patients. There is consensus that 
beta-blockers and ACEIs are complementary, and can be started together as soon as the diagnosis of 
HFrEF is made. There is no evidence favouring the initiation of treatment with a beta-blocker before 
an ACEI has been started (127). 
An individual patient data meta-analysis of all the major beta-blocker trials in HFrEF has shown no 
benefit on hospital admissions and mortality in the subgroup of patients with HFrEF who are in AF 
(128). 
1.7.1.3 Aldosterone receptor antagonists (ARA) 
ARAs (spironolactone and eplerenone) block receptors that bind aldosterone and, with different 
degrees of affinity, other steroid hormone (e.g. corticosteroids, androgens) receptors. 
Spironolactone or eplerenone are recommended in all symptomatic patients (despite treatment 
with an ACEI and a beta-blocker) with HFrEF and LVEF ≤35%, to reduce mortality and HF 
hospitalization (129,130). 
Caution should be exercised when ARAs are used in patients with impaired renal function and in 
those with serum potassium levels >5.0 mmol/L. 
1.7.1.4 Diuretics 
Diuretics are recommended to reduce the signs and symptoms of congestion in patients with HF. A 
Cochrane meta-analysis has shown that in patients with chronic HF, loop and thiazide diuretics 
appear to reduce the risk of death and worsening HF compared with placebo, and compared with an 
active control, diuretics appear to improve exercise capacity (131,132). 
Loop diuretics produce a more intense and shorter diuresis than thiazides, although they act 
synergistically and the combination may be used to treat resistant oedema. However, aggressive 
diuresis has diverse consequences, including electrolyte disturbances and consequent arrhythmias, 
intravascular depletion, hypotension, and renal dysfunction. Worsening renal function makes further 
diuresis more difficult and worsens the prognosis in HF patients (132,133). 
1.7.1.5 Angiotensin receptor neprilysin inhibitor 
A new therapeutic class of agents acting on the renin–angiotensin–aldosterone system (RAAS) and 
the neutral endopeptidase system has been developed [angiotensin receptor neprilysin inhibitor 
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(ARNI)]. The first in this class is a combination of valsartan and sacubitril in a single substance. By 
inhibiting neprilysin, the degradation of natriuretic peptide (NP), bradykinin and other peptides is 
slowed. High circulating A-type natriuretic peptide (ANP) and BNP exert physiological effects through 
binding to NP receptors and the augmented generation of cGMP, thereby enhancing diuresis, 
natriuresis and myocardial relaxation and anti-remodelling. ANP and BNP also inhibit renin and 
aldosterone secretion. Selective AT1-receptor blockade reduces vasoconstriction, sodium and water 
retention and myocardial hypertrophy (134,135). This group is recommended as a replacement for 
an ACE-I to further reduce hospitalisation and death in HF patients. 
1.7.1.6 If-channel inhibitor 
Ivabradine slows the heart rate through inhibition of the “If” channel in the sinus node and therefore 
should only be used for patients in sinus rhythm. Ivabradine reduced the combined endpoint of 
mortality or hospitalisation for HF in patients with symptomatic HFrEF or LVEF ≤35%, in sinus rhythm 
and with a heart rate ≥70 beats per minute (bpm) who had been hospitalised for HF within the 
previous 12 months, receiving treatment with an evidence-based dose of beta-blocker (or maximum 
tolerated dose), an ACEI (or ARB) and an mineralocorticoid receptor antagonist (MRA) (136). 
1.7.1.7 Angiotensin II type I receptor blockers (ARBs) 
ARBs are recommended only as an alternative in patients intolerant of an ACEI (137). Candesartan 
has been shown to reduce cardiovascular mortality (137). Valsartan showed an effect on 
hospitalisation for HF (but not on all-cause hospitalisations) in patients with HFrEF receiving 
background ACEIs (138). 
1.7.1.8 Digoxin 
Digoxin may be considered in patients in sinus rhythm with symptomatic HFrEF to reduce the risk of 
hospitalisation (both all-cause and HF hospitalisations) (136) although its effect on top of beta-
blockers has never been tested. In patients with symptomatic HF and AF, digoxin may be useful to 
slow a rapid ventricular rate, but it is only recommended for the treatment of patients with HFrEF 
and AF with rapid ventricular rate when other therapeutic options cannot be pursued (139,140). 
1.7.1.9 Implantable cardioverter defibrillator (ICD) 
ICDs are effective in preventing bradycardia and correcting potentially lethal ventricular arrhythmias.  
ICD reduces mortality in survivors of cardiac arrest and in patients who have experienced sustained 
symptomatic ventricular arrhythmias. The device is recommended in such patients when the intent 
is to increase survival; the decision to implant should take into account the patient’s view and their 
quality of life, the LVEF (survival benefit is uncertain when the LVEF is > 35%) and the absence of 
other diseases likely to cause death within the following year (141,142). 
1.7.2 Treatment of heart failure with preserved ejection fraction  
Unlike systolic heart failure, for which multiple effective medications are available, the 
pharmacologic treatment of HFpEF is disappointing. No agents have been shown to improve survival 
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or to enhance quality of life (QOL), exercise tolerance, or diastolic function. The mainstay of medical 
treatment should be prevention for persons at risk for HFpEF and control of blood pressure, heart 
rate, and fluid status in patients with established disease (112). For those patients with concomitant 
medical problems that are associated with HFpEF, management of the underlying condition, such as 
obstructive sleep apnoea, is reasonable, although there are no outcomes data to support this 
approach. In patients with type 2 diabetes mellitus, elevated serum triglyceride levels are associated 
with myocardial steatosis, which in turn causes diastolic dysfunction. Prolonged caloric restriction 
reduces myocardial triglyceride content and improves diastolic heart function (143). 
 
1.8. Mitral regurgitation (MR) 
1.8.1 Mitral regurgitation in heart failure 
The exact incidence and prevalence of mitral regurgitation (MR) is unknown, but it probably exceeds 
five million worldwide (144); MR is the second most common type of heart valve disease requiring 
surgery in Europe (145). Chronic volume overload by MR plays a large contributing role in the 
development of heart failure (146,147), but could also develop in response to altered LV geometry 
(64%) in ischaemic MR detected by echocardiography in post Q-wave MI patients (22) and abnormal 
afterload (72%) in hypertension (HTN) and aortic valve stenosis (AS) (148). Moderate or severe MR 
was also an independent predictor of new onset HF in patients with ischaemic LV dysfunction 
(relative risk: 3.2 [95% CI: 1.9 to 5.2], p = 0.0001) (22).  
1.8.2 Primary & Secondary Mitral Regurgitation 
MR is classified as primary (also known as organic) when principally due to a structural or 
degenerative abnormality of the mitral valve (MV), whether of the leaflets, chordae tendineae, 
papillary muscles, or mitral annulus. Secondary (also known as functional) MR occurs in the absence 
of organic MV disease, usually from left ventricular (LV) dysfunction. It is more common than 
primary MR (149), is associated with a worse prognosis (compounded by the underlying 
cardiomyopathy), and (in contrast to primary MR) the benefits of MV surgery are uncertain (22). 
 
1.8.3 Pathophysiology of MR. Ischaemic & non-ischaemic MR. 
The mitral valve consists of 2 leaflets (anterior and posterior) sitting within the annulus (FIGURE 4). 




FIGURE 4. Mitral valve anatomy (22). 
A subvalvular apparatus, comprising 2 papillary muscles (anterolateral and posteromedial) arising 
from the LV myocardium and the chordae tendineae, supports the leaflets. LV dilation due to 
ischaemic or non-ischaemic cardiomyopathy secondarily impairs leaflet coaptation of a structurally 
normal MV, resulting in secondary MR. Specifically, LV dysfunction and remodelling lead to apical 
and lateral papillary muscle displacement, resulting in leaflet tethering (150), dilation and flattening 
of the mitral annulus, and reduced valve closing forces. Because these changes are dependent on 




FIGURE 5. Secondary MR due to LV dilatation (22) 
(A) A representative echocardiogram and diagram of ischemic MR, with a posteriorly directed jet. (B) A representative echocardiogram 
and diagram of MR due to idiopathic dilated cardiomyopathy, with a central jet. Note the lateral displacement of the papillary muscles 
(arrows). Apical displacement is also typically present, although less well demonstrated in these views. LVOT =left ventricular outflow 
tract; MR = mitral regurgitation; TEE = transoesophageal echocardiography. 
Papillary muscle displacement occurs as a result of global LV enlargement or focal myocardial 
scarring, and can affect 1 or both papillary muscles, causing posteriorly directed or central MR 
(Figure 5) (151). With chronic MR, the mitral leaflet area may increase up to 35% over time, an 
adaptive response that minimizes the degree of regurgitation; insufficient leaflet remodelling may 
contribute to severe MR (152,153). However, even in patients with increased mitral leaflet area, 
papillary muscle displacement with subsequent decreased coaptation length may still result in 
significant MR (153).  
Non-ischaemic MR, most commonly due to longstanding hypertension or idiopathic dilated 
cardiomyopathy, is characterized by global LV dilation with increased sphericity and (typically) a 
centrally located regurgitant jet. Symmetric mitral annular dilation is greatest in the septal-lateral 




1.8.4 Mortality in heart failure patients 
Mortality increases with clinical severity and may be as high as 60% within 1 year for patients with 
severe (NYHA Class IV) heart failure (158). Five-year mortality in the Framingham Study was 75% in 
men and 62% in women (158).  HF patients experience relatively low in-hospital mortality but are at 
much higher risk for early post-discharge readmission and mortality. The in-hospital mortality rate 
for patients hospitalised with this condition is 20-30% (125,126). In general, the mortality rate in 
patients with CHF is 3 to 5 times that of men and women of a similar age without heart failure (128). 
1.8.4.1 Mortality in heart failure patients with mitral regurgitation 
A strong association between severity of secondary MR and both all-cause mortality and heart 
failure hospitalisations has been reported widely (159). Possibly development of myocardial damage 
after Q-wave MI altered mitral valve apparatus in majority of patients (64%) leading to a 
development of  ischaemic MR (159) which was a powerful, independent  predictor  of long-term all-
cause mortality. In a study from the Duke Cardiovascular Databank, qualitatively assessed 3+ to 4+ 
MR on left ventriculography was present in 29.8% of 2,057 HF patients with an LVEF <40% and was 
an independent predictor of 5-year mortality (160). Among 1,256 patients with dilated 
cardiomyopathy at the Mayo Clinic, quantitatively assessed severe secondary MR was present in 
24% of patients, and was an independent predictor of death or HF hospitalisation at median 2.5-year 
follow-up, independent of LVEF (161). This relationship was present separately for death and HF 
hospitalisations, and in patients with ischaemic and non-ischaemic MR. Secondary MR is a powerful 
predictor of death or transplant, even with less severe HF. Thus secondary MR is widely accepted as 
a predictor of poor prognosis in patients with primary LV dysfunction and HF. Whether reducing MR 
improves patient prognosis remain unknown.  
The recent European based study showed that severe functional MR was a significant predictor of 
mortality, independent of clinical, and echocardiographic confounders, optimal medical therapy and 
neurohumoral activation. Subanalysis revealed that severe functional MR was associated with poor 
outcome in an intermediate-failure phenotype of HFrEF i.e. patients with NYHA class II and III, 
moderately reduced left ventricular function (162). 
 
1.8.5 Evaluation of secondary MR 
Comprehensive evaluation of the patient with HF and secondary MR requires a detailed medical 
history and physical examination, with laboratory, electrocardiographic, and echocardiographic 
assessment. Most important is an accurate appraisal of the functional limitations attributable to HF, 
the MV anatomy and severity of MR, and evaluation of the left and right heart circulation, including 
measurement of chamber size and cardiac pressures (22). By integrating these findings, secondary 
MR can be categorized into 4 stages that define prognosis and guide therapy: 1) at risk of secondary 
MR; 2) progressive secondary MR; 3) asymptomatic severe secondary MR; and 4) symptomatic 
severe secondary MR (TABLE 5) (163). 
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1.8.6 Treatment of HF patients with MR  
The goals of therapy in patients with secondary MR are to improve symptoms and quality of life, 
reduce HF hospitalisations, and potentially improve survival. To date, the most effective therapies 
for secondary MR are aimed at the underlying LV dysfunction, including guideline-directed medical 
therapy (GDMT) for HF and biventricular pacing (CRT) when appropriate. Coronary revascularization 
may also be considered in patients with extensive ischaemia and preserved myocardial viability, 
although it rarely markedly reduces or eliminates secondary MR. The role of surgical and 
transcatheter MV repair or replacement to interrupt the progressive cycle of LV volume overload → 
LV dilation → secondary MR → increasing LV volume overload and dilation → increasing MR is less 
well established, although some patients may symptomatically benefit. Finally, in patients with 
severe HF and secondary MR refractory to standard therapies, consideration should be given to 
mechanical LV assist devices and heart transplantation (22). 
1.8.6.1 Medical therapy for secondary MR 
So far medical therapy for HF remains first-line treatment for patients with secondary MR  (163). 
Nevertheless, the outcomes remain poor:  among 404 secondary MR patients treated with medical 
therapy, 4-year cardiac mortality occurred in 43% and 45% with moderate and severe MR, 
respectively, compared with only 6% with mild MR (p = 0.003)(164). Moderate or severe MR was 
also an independent predictor of new onset HF in patients with ischaemic LV dysfunction (relative 
risk: 3.2 [95% CI: 1.9 to 5.2], p = 0.0001). By reversing LV remodelling, maximal GDMT may 
secondarily reduce severe MR. Surprisingly, however, few studies have examined the effect of 
medical therapies on secondary MR (22). 
1.8.6.2 Surgery for secondary MR 
Surgical options for secondary MR include surgical MV repair and replacement, mechanical LV assist 
devices, and orthotopic heart transplantation. Although MV surgery has never clearly been 
demonstrated to alter the natural history of the primary myocardial disease (dilated 
cardiomyopathy) or improve survival and long term outcome (165-167). Isolated MV annuloplasty in 
severe secondary MR and LVEF ≤ 30% (165) did not present any advantage at 5.5-year follow-up. 
Lack of success with medical and surgical therapy is certainly secondary to advanced myocardial 
damage but also might reflect heterogeneity of MR mechanism in this group of patients. 
TABLE 5. Stages of Secondary (Functional) MR(163) 





A: At risk of MR • Normal valve 
leaflets, chords, 




• No MR jet or 
small central jet 
area <20% LA on 
Doppler 
• Small vena 
• Normal or 
mildly dilated LV 




• Symptoms due 
to coronary 
ischaemia or HF 
may be present 























• Annular dilation 
with mild loss of 
central 
coaptation of the 
mitral leaflets 
• EROA <0.20 
cm2 
• Regurgitant 
volume <30 ml 
• Regurgitant 
fraction <50% 
• Regional wall 
motion 
abnormalities 
with reduced LV 
systolic function 






• Symptoms due 
to coronary 
ischaemia or HF 
may be present 





  severe MR 
• Regional wall 
motion 
abnormalities 




• Annular dilation 
with severe loss 
of central 
coaptation of the 
mitral leaflets 
• EROA ≥ 0.20 
cm2 
• Regurgitant 
volume ≥ 30 ml 
• Regurgitant 
fraction ≥ 50% 
 
• Regional wall 
motion 
abnormalities 
with reduced LV 
systolic function 






• Symptoms due 
to coronary 
ischaemia or HF 
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• Regional wall 
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tethering of 
mitral leaflet   
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• Regurgitant 
fraction ≥ 50% 
• Regional wall 
motion 
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with reduced LV 
systolic function 
• LV dilation and 
systolic 
• HF symptoms 








• Annular dilation 
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of central 
coaptation of the 









EROA = effective regurgitant orifice area; HF = heart failure; LA = left atrium; LV = left ventricular; MR = mitral regurgitation. 
1.8.6.3 Cardiac resynchronization therapy (CRT) for MR 
CRT is a well-established treatment for HF in selected patients with LV dyssynchrony. CRT is a Class I 
recommendation for patients in sinus rhythm with New York Heart Association (NYHA) functional 
class II to IV symptoms on medical therapy with LVEF ≤ 35%, left bundle branch block (LBBB), and 
QRS duration ≥ 150 ms. CRT may also be useful in patients with LVEF ≤ 35%, with sinus rhythm and 
non-LBBB pattern with QRS duration ≥ 150 ms, and in those with LBBB and QRS duration 120 to 149 
ms (Class IIa indications) (121). Randomized trials demonstrated improvements in both survival and 
HF rehospitalisation rates in patients treated with CRT with or without a defibrillator, along with 
reductions in LV end-diastolic and end-systolic dimensions and improved LVEF (168). In subgroup of 
HF patients with dyssynchrony resynchronisation therapy showed a reduction in MR severity with 
restoration of synchronous ventricular contraction and reverse LV remodelling (169). But this effect 
of CRT on secondary MR was not seen in absence of dyssynchrony (170).   
1.8.6.4 The MitraClip 
Recent development of transcatheter interventions appears promising. The MitraClip, the first 
percutaneous mitral valve repair device, provides the next therapeutic option for severe MR patients 
(171).  The MitraClip is a polyester-covered cobalt-chromium clip inserted via the femoral vein and 
advanced under transoesophageal echocardiographic guidance into the LA following trans-septal 
puncture (Figure 6). The clip is opened, positioned above the regurgitant jet, and advanced into the 
LV. It is then retracted to grasp the free edges of the mitral leaflets, the grippers are dropped, and 
the clip is closed and released, emulating a surgical edge-to-edge repair (87). Multiple clips may be 




FIGURE 6. Mitral Clip device.  Close-up views of the MitraClip device’s fabric-covered clip (left) and guiding catheter with clip 
delivery system (right). Images courtesy of Abbott Vascular, Menlo Park, California (22). 
In-hospital (2.9%) and 1-year (15.3%) mortality were similar in patients with secondary and primary 
MR after procedure, although rehospitalisation for HF was more common in the secondary MR 
group (25.8% vs. 12.0%, p = 0.009). At 1 year, severe MR was present in only 6% of patients. The 
MitraClip has also been used successfully in HF patients who are non-responders to CRT (an 
especially high-risk group), with resultant improvements in MR grade, functional capacity, and LV 
remodelling (170). In the 25-center, 8-country, 2011 to 2012 European Sentinel Pilot Registry, 72% of 
628 MitraClip-treated patients had secondary MR, 86% had NYHA functional class III/IV symptoms, 
and the mean EuroSCORE was 20.4. Acute procedural success was high (95.4%), with multiple clips 
used in 39% of patients (174).  
Consequently, the 2017 European Society of Cardiology guidelines suggested the use of 
transcatheter mitral valve treatment in symptomatic patients who are at high surgical risk or are 
inoperable (175). Percutaneous edge-to-edge repair is generally safe and can improve symptoms 
and provide reverse LV remodelling despite higher rate of residual mitral regurgitation at 5 years 
compared to surgical repair (176). 
1.9. Cost of Heart Failure to Healthcare Systems, role of mitral regurgitation 
1.9.1 Proportion of heart failure expenditure to total healthcare budget 
In developed countries, total expenditure on HF ranges between 1-2% of the total healthcare 
budgets. The healthcare costs increases 8-30 fold with worsening of functional NYHA class (177,178) 
and driven by hospitalisations due to development of acute or exacerbation of chronic HF.  HF 
accounts up to 5% of American and European hospital admissions. Global per capita spending in 
2012 was approximately $24/annum (179). Health expenditure on chronic HF includes both direct 




1.9.2 Cost breakdown for heart failure expenditure 
The analytical results showed that from the perspective of the health care provider the direct 
treatment costs are to be listed as the following sequence (180): 
1. Costs of hospitalisation: these include the costs of hospitalisation, nursing staff, blood 
products, medical equipment, anaesthesia, medical examinations, diagnostic tests and the costs of 
the hospital ward. The weighting of this indicator amounts to a relative frequency of 26.09%. This 
percentage is the highest value among the identified indicators and is thus ranked first. 
2. Costs of medical services: these include the costs of diagnosis, general practitioners, medical 
specialists, pharmacists, home calls, ambulatory care services, therapists, primary care, ambulatory 
treatment and the costs of the medical care. The weighting of this indicator amounts to a relative 
frequency of 23.91%. 
3. Costs of medication: these include the costs of drugs that were prescribed to the chronic HF 
patients during their treatment. The resulting indicator emphasis is 21.74%. 
4. Costs of intervention: these include costs of telemonitoring (TM) equipment, TM trained 
nurses, TM service, TM monitoring, TM support and consulting, TM training as well as the TM based 
medical supervision.  The relative frequency of the indicator thus  amounts to 17.39%. 
5. Costs of rehabilitation and emergency services: these include costs of the emergency ward 
and the rehabilitation of chronic HF patients.  The weighting of the indicator amounts to a value of 
10.87%. 
The recent data, where 197 countries were included (98.7% of the world`s population), suggests the 
overall economic cost of HF in 2012 was estimated at $108 billion per annum. Direct costs accounted 
for 60% ($65 billion) and indirect costs accounted for 40% ($43 billion) of the overall spend (179). 
Estimated global values of direct, indirect and total costs of HF for  the UK (stratified by WDI 
economic status) in year 2012 direct costs accounted $3223 million, indirect costs - $1461 million 
and overall HF costs - $4684 million (181). 
1.9.3 Medical costs: hospitalisation and investigation 
Almost two-thirds of total healthcare expenditure on HF is due to hospitalisation (182,183) and re-
admissions (32,35). Inpatient care costs account for 50- 70% of the health costs of patients with HF 
(184-186). Furthermore, highly prevalent co-morbidities in HF (187) add to frequency of hospital 
admissions. For example, cardiovascular events, such as stroke and myocardial infarction, and renal 
failure (188) have a significant impact on hospital admissions. 
1.9.3.1 Diagnostic work-up costs 
The costs of in-patient investigations represent a substantial proportion of expenditure on 
hospitalisation. One estimate of investigation costs quantified the total cost of investigation as £57.4 
million in the UK per annum (182). This might be grossly underestimated as the cost of 




TABLE 6: Unit cost of included diagnostic tests/imaging (190) 
Diagnostic Unit cost Source 
BNP or NT-proBNP test £ 28.13 St George NHS Trust 
Departmental simple trans-
thoracic echocardiogram 
£ 62.60 NHS Reference costs schedule 
2012-13 
 
1.9.3.2 Acute care staffing costs 
The NICE guideline development group selected the general physician, the cardiologist and the heart 
failure specialist nurse (HFSN) as the key roles whose time requirement would differ between 
standard and specialist arrangements of inpatient heart failure care. Other roles and disciplines were 
considered but excluded on the basis that the level and nature of their input would not differ. 
On behalf of the National Clinical Guideline Centre (NCGC), the National Institute for Cardiology 
Outcomes Research (NICOR) conducted an online survey of 145 NHS Trusts in England and NHS 
Health Boards in Wales in order to estimate how much time each discipline spent on patient related 
activities per patient per week in cardiology and general medical wards. The guideline development 
group formulated the questions. 53 Trusts submitted usable responses. Three submitted unusable 
responses. Estimates are shown in TABLE 7.(190) 
TABLE 7. Time spent on patient related activities by discipline 
 
The cost per hour of a cardiologist and general physician is the same, and consultant grade was 
selected as a conservative simplification. The HFSN was assumed to be NHS Agenda for Change Band 
7. Hourly rates were obtained from the Personal Social Services Research Unit Handbook 2013 and 






TABLE 8. Unit cost of hospital staff included in the model (191) 
 
 
1.9.3.3 Acute care bed costs 
The model included hospital costs other than staff, treatments and diagnostic tests in order to 
reflect the additional cost of extended length of hospitalisation resultant from incorrect diagnostic 
work-up. The weighted unit cost for a bed day was calculated from the NHS reference costs EB03H 
and EB03I (Heart Failure or Shock with and without complications) and was £232.09 (Department of 
Health. NHS reference costs 2012-13). The median length of stay was 8 days, and the consequence 
of incorrect diagnosis was an additional 2 days stay, as advised by the guideline development group 
(192). 
For comparison, in the US-based prospective observational study (SUPPORT) of procedures and 
outcomes in patients hospitalised with an exacerbation of chronic HF, cost-of in-patient care 
adjusted for disease-severity was $2100 (42.9%) more expensive for treatment by a cardiologist than 
by a generalist (193). It is not clear whether such differences in treatment alter long-term outcomes.  
1.9.4 Medical costs: medications  
Medical therapy has been proven to have significant effect on mortality and morbidity in HF (194). It 
takes up a relatively small proportion in overall costs (21.74%) per patient (180,182,186), but  
represents a substantial source of healthcare expenditure given the high prevalence of CHF in the 
community. Treatment with ACE-inhibitors and beta-blockers with the addition of angiotensin 
receptor blockers and/or aldosterone antagonists in more advanced stages of the disease is still the 
mainstay of HF therapy aiming at reducing symptoms, improving functional status and survival, and 
reducing hospitalisation.  Diuretics and other drugs remain optional with no firm evidence from 
randomised trials (131,132). Thus, most HF patients take a large number of pills to treat their chronic 
HF and the various co-morbidities that are commonly present. Consequently, the costs for drug 
treatment are high and have been estimated to be $3.2 billion per year in the USA (195) and £128.6 
million in the UK (186). Angiotensin converting enzyme inhibitors (ACE-i) (196,197) or Angiotensin II 
type I receptor blockers (ARBs) (137,138), b-blockers (198-201), Mineralocorticoid/aldosterone 
receptor antagonists (MRAs) (129,130) are an established and cost-effective therapy in heart failure. 




The National Clinical Guideline Centre has estimated the cost of left ventricular systolic dysfunction 
(LVSD) disease modifying drug therapy and included into its study LVSD patients during the 
hospitalised periods and the non-hospitalised periods. Three classes of LVSD drug were included 
because they form the gold standard of care in this group of patients. The weighted average cost per 
day was calculated using the Prescription Cost Analysis for England 2012 (203). The cost of each drug 
was weighted by number of prescriptions (although it was not possible to isolate this to 
prescriptions specifically for heart failure). Unit costs are shown in TABLE 9 and 90 day treatment 
costs, by management strategy are given in TABLE 10.(190) 
TABLE 9. Unit cost of LVSD drugs 
 
(a) Prescription cost analysis(203) 
TABLE 10. LVSD drug treatment cost by care received 
 
(a) Based on the probability of being prescribed treatment (National heart failure audit). National Institute for Cardiology Outcomes 
Research (NICOR). Secondary analysis of the National Heart Failure Audits of England and Wales 2009 - 2013 (unpublished data), 2014 
The cost of other standard drugs such as diuretics was not included because the level of their use 
was assumed to be equivalent in standard and specialist management. 
 
1.9.5 Medical costs: implantable electronic devices and surgical intervention 
1.9.5.1 The cost of implantable electronic devices 
Some of the cardiovascular implantable electronic devices (cardiac pacemakers, implantable 
cardioverter-defibrillators and etc) have become an effective treatment option in selected HF 
patients. In a recent report by Groeneveld et al., time-series regressions between 2003 and 2006 in 
the USA indicated that a 1% increase in the use of implantable cardioverter-defibrillators (ICD) use in 
the HF population resulted in $627 higher mean costs (P < 0.001). In aggregate, the cost increase 
attributable to ICDs was $893 million (29% of the total growth)(204).  
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Based on average selling prices aggregated across all manufacturers of ICDs sold in the UK to the 
NHS in the financial year of 2011, the cost of a complete ICD system was estimated at £9692, the 
cost of a complete CRT‑P system was estimated to be £3411 and CRT‑D system was £12,293. (205) 
1.9.5.2 The cost of surgical revascularisation 
Surgical intervention in CHF remains of limited use therefore the total cost is insignificant - 2.74% of 
the total healthcare expenditure on heart failure (189). In the United Kingdom in 1990-91, the costs 
for surgical revascularisation and cardiac transplantation in CHF patients were estimated at £7.2 and 
£2.66 million respectively (189). The latest cost of coronary bypass grafting according to the NICE 
(2011) has not changed significantly and in 2008-2009 was £7.959  (206). LVADs cost £80,569 
($127,887) at 2011 prices, which is cheaper than previous generation device (207). 
1.9.5.3 Valvular disease in context of HF 
The data on costs of valvular disease in context of HF, especially mitral regurgitation (MR) is also 
sparse. The French study suggested that presence of HF led to significant differences in cost of care 
in patients with MR (27). Non-surgical patients with HF and MR had high 12 months mortality and 
LOS with total cost of care 13,538€ vs 9957€ in patients without HF. Rehabilitation costs were also 
different.  Patients with MR and HF who were managed medically consumed 45% (€ 132.3 million) of 
the overall annual cost of management of patients with MR (148).  
1.9.6 Cost of rehabilitation. Follow up cost 
Costs arising during non-hospitalised periods, as a result of an acute admission, include the following 
on the basis that they would differ between standard and specialist management: 
• Heart failure drug therapy (described above) 
•  Hospital out-patient visits 
•  Primary care GP visits 
•  Community HFSN visits 
The cost of cardiac rehabilitation was not included because the uptake of this service is low (11%) 
and cost is uncertain (208). 
The occurrence and frequency of health system contacts other than acute admissions are specific to 
whether or not referral had been made to follow-on services. The national heart failure audit 2013 







TABLE 11. Probability of being referred to follow-on services (209) 
Follow-on service Specialist heart failure 
team on a cardiology 
ward (National Heart 
Failure Audit 2012-13) 
(NHFA) 
Specialist heart failure 
team on a general 
ward (inferred) 
General medical team 
on a general ward 
(NHFA 2012-13) 
Cardiology follow-up 71% 50% 22% 
Heart Failure nurse 
follow-up(a) 
68% 71% 23% 
(a) HFSN follow-up was costed as a home visiting based service 
 
The unit costs of follow-on services and tests are given in TABLE 12 (208) 
TABLE 12. Unit cost of follow-on services 
Follow-on service/type of 
contact 
Unit cost Source 
GP visit £37 Personal Social Services 
Research Unit Handbook 2013 
(191). 11.7 minute 
consultation. 
Community HSFN visit £42 Personal Social Services 
Research Unit Handbook 2013 
(191). Nurse Specialist 
(Community), 1 hour. 
Hospital outpatient visit £131 NHS Reference costs schedule 
2012-13. (Department of 
Health. NHS reference costs 
2012-13). Cardiology outpatient 
visit. 
 
1.9.7 Non-medical costs 
The non-medical costs of CHF are difficult to estimate.  These costs include those of lost earnings, 
sickness benefits, hospital transportation and social welfare support and the wider effect on 
patient’s families. For example, in one state in America, the transportation costs of hospital out-
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patient visits have been estimated to be greater than those spent on drug therapy (210). Socio-
demographic inequalities have a certain impact on management and access to therapies (211).   
1.10. Conclusion 
In summary, during the last decades HF costs have substantially increased and will remain a 
significant economic burden on healthcare systems worldwide. The total impact of HF on the public 
is probably not well defined given the sparsity of data on the non-medical impact of HF public 
service. Although the prognostic impact of secondary MR is well understood, it is not clear if mitral 
insufficiency is the main driver of hospital admissions and whether correction of secondary MR by 
less invasive structural intervention will alter the course of disease. Further observational and 
interventional studies are needed to address this problem.  
1.11. The key aims of MRAHF trial. 
The MRAHF trial is aimed to study the incidence of significant MR in patients presenting acutely to 
district general hospital with symptoms of breathlessness and palpitations requiring hospital 
admission. The previous history of all cause hospital admissions and admissions with heart failure 
will be collected retrospectively to calculate the economic impact of significant MR. The objectives 
are: 
1. To study the prevalence of MR of any severity in patients admitted acutely with symptoms 
of HF and its effect on LV function and patients prognosis. 
2. To perform analysis of the economic impact of managements of patients with HF driven by 
significant MR during index acute admission and history of previous inpatient spells.  
3. To determine how many acute HF patients are managed according to the National Institute 
for Health and Care Excellence (NICE) guidelines and to compare with the outcome and 











CHAPTER 2: METHODS 
 
2.1. Patients recruitment 
2.1.1 Clinical data collection 
The suitability of patients for the MRAHF study was established once all heart failure patients had 
been screened within 24 hours after admission following which they were recruited and consented. 
The recruitment process took place at St Peter`s Hospital (SPH), which is a part of Ashford and St 
Peter`s NHS Trust. The following data has been collected from every patient: demographics, number 
of previous admissions to the SPH and the length of stay in the hospital during the last 12 months, 
24 months and 36 months, admissions with primary diagnosis of heart failure for the same period of 
time, HF symptoms at the moment of presentation, HF stage by NYHA, comorbidities like 
hypertension, IHD, diabetes mellitus, CKD, CVA, COPD, presence of smoking and a recent blood test 
results.  
2.1.2 Investigations 
Echocardiography and cardiology review done within 36 months and at the current admission were 
registered. ECG results, CXR and the list of HF medications taken by patient were also collected. 
Every patient had their serum BNP done and thorough transthoracic echocardiography performed 
for the assessment of mitral regurgitation (MR) severity, left ventricular function and right heart 
abnormalities. 
2.1.3 Ethical approval. Recruitment site and durability 
The ethical approval was done by the North of Scotland Research Ethics Committee (REC number 
16/NS/0047; 6th of June 2016). Recruitment was started on 4/07/2016 and carried out by two 
Clinical Research Fellows with occasional help from Research nurses.  All staff were based at St 
Peter`s Hospital.  During the 1 year and 2 months that this study has been running, a total of 500 
patients have been recruited. 447 patients were included into analysis after all exclusions. 
2.2. Recruitment criteria (Inclusion & Exclusion) 
2.2.1 Inclusion criteria 
Selection for this study had to meet certain inclusion criteria. Patients could be eligible for our study 
if their age was from 18 years to 100 years, both male or female gender. The main inclusion criteria 
were clinical signs and symptoms of acute heart failure or decompensated chronic heart failure. 
After that, they were required to have a bedside B-type natriuretic peptide (BNP) level of > 100 ng/L 
-   according to the European  Society of Cardiology the upper limit of normal BNP in the in the acute 
setting (19). The use of NPs is recommended for ruling out HF, but not to establish the diagnosis 
(19). Therefore, our choice to have 100 ng/L as the cut off, aimed to reduce the error of missing 





2.2.2 Exclusion criteria 
The main exclusion criteria needed to be met was a bedside serum BNP level <30 ng/L. Also we were 
aiming to measure BNP level and recruit a suitable patient within the first 2 days of hospital  
admission. Patients who did not meet these requirements, were excluded from the study along with 
patients who were not within the specified age range of 18-100 years. 
2.3. Data Collection 
2.3.1 Screening of patients 
Before collecting any data, patients were screened first using the hospital electronic database, which 
include on-take and clinical handover lists.  All patients admitted with symptoms of HF (shortness of 
breath, peripheral oedema, palpitations and irregular heart beat) were assessed by a Clinical 
Research Fellow. After individuals with suspected acute heart failure were selected, their clinical 
notes were then carefully screened and further clinical examinations and assessments to identify the 
suitability of a patient for our study were carried out. 
2.3.2 Consent for the study 
Those patients with clear evidence of acute HF were given as much information as they were 
required to make an informed decision about participation in the study. When the patient decided 
to participate they were given an information sheet to keep and asked to sign a consent form.  
2.3.3 Measurement of Brain Natriuretic Peptide (BNP) plasma level 
From those who were consented, a blood sample was taken for bedside i-STAT BNP test (i-STAT 1 
Analyser “Immuno-Ready”). The i-STAT BNP monitor was provided by Abbott POCT ltd and 
calibrated and used according to their instructions. The clinical team remained blind to the results of 
i-STAT BNP unless it was formally requested via routine hospital requesting system.  
The i-STAT BNP test is an in vitro diagnostic test for the quantitative measurement of B-type 
natriuretic peptide (BNP) in plasma samples using EDTA as the anticoagulant.  
The i-STAT BNP test cartridge uses a two-site enzyme-linked immunosorbent assay (ELISA) method. 
Antibodies specific for BNP are located on an electrochemical sensor fabricated on a silicon chip. The 
whole blood or plasma sample is brought into contact with the sensors allowing the enzyme 
conjugate to dissolve into the sample. The BNP within the sample becomes labelled with alkaline 
phosphatase and is captured onto the surface of the electrochemical sensor during an incubation 
period of approximately seven minutes. The enzyme bound to the antibody/antigen/antibody 
sandwich cleaves the substrate releasing an electrochemically detectable product. The 
electrochemical sensor measures this enzyme product which is proportional to the concentration of 




2.3.4 Clinical data 
Once i-STAT BNP confirmed the diagnosis of HF the following data had been taken from patient`s 
clinical notes: demographic data (date of birth, gender, ethnicity), clinical data (symptoms, vital 
signs, ECG, CXR, NYHA class), number of previous admissions in total and with HF for the last 1 year, 
2 years and 3 years, previous and current length of hospital stay, cardiology appointments and 
echocardiography scans for the last 3 years and at the current admission.  Also, comorbidities like 
known mitral regurgitation, ischaemic heart disease, hypertension, diabetes mellitus, chronic kidney 
disease, chronic obstructive pulmonary disease, previous cerebrovascular accident and presence of 
smoking, mortality in 1, 3, 6 months and 1 year had been recorded.  
2.3.5 Pharmacological data 
To complete the clinical data collection, the following pharmacological data had been collected: 
compliance with HF treatment, use of mineralocorticoid receptor antagonists (MRAs), Angiotensin 
Converting Enzyme inhibitors (ACEi), Angiotensin II Receptor Blockers (ARBs), Angiotensin receptor 
blockers with Neprilysin inhibitors (ARNIs), beta-blockers, blood vessel dilators, Calcium channel 
blockers (CCBs), digoxin, diuretics, selective sinus node inhibitors and potassium or magnesium 
supplementation. 
2.4. Echocardiography 
2.4.1 Echocardiography protocol and data storage 
After the data mentioned above was collected, a transthoracic echocardiography (TTE) was 
performed on every patient by a Clinical Research Fellow using the GE Vivid S70 ultrasound machine. 
The Research Fellow was fully accredited by the British Society of Echocardiography (BSE) with 
reaccreditation having been completed in 2017 during the patient recruitment for our study.   
Over 90 % of our patients were scanned by a single echocardiographer (Observer 1) to reduce intra 
observer variability. All echocardiography studies were screened by another echocardiographer 
(Observer 2), to minimise inter observer  variability in our studies.  Analysis was done by Bland – 










Figure 7. Bland – Altman plot for regurgitant volume assessment (Observer 1& Observer 2). 
 
 
Figure 8. Bland – Altman plot for Effective orifice area assessment (Observer 1 & Observer 2) 
 
 
Every echocardiography study followed BSE recommendations and included parasternal, apical and 
subcostal approach for each patient with up to 5 views from every approach assessing the heart 
anatomy and function by two dimensional echo (2D), M-mode, Colour Doppler,  tissue doppler 
imaging (TDI), pulse wave doppler (PW), continuous wave doppler (CW), Strain and Strain rate. The 
data from the Echo has been analysed on-line and off-line using ECHOPAC version 201. 
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The cardiology clinical team, who were working separately from us, also remained blinded to the 
results of echocardiography unless there had been any severe, life threatening abnormalities 
identified that required urgent management for the patient`s safety. All studies had been exported 
to two external hard drives to secure our database. 
 
Figure 9. MR quantification – PISA method 
2.4.2 Mitral Regurgitation (MR) 
The mitral regurgitation was determined by using quantitative, semi-quantitative and qualitative 
methods.  The mitral valve morphology assessment and colour Doppler imaging were part of our 
qualitative method. Pulmonary venous flow and vena contracta were used for semi quantitative 
assessment.  
For quantitative assessment of MR severity PISA was the method of choice to estimate  effective 
regurgitant orifice area by analysing of flow convergence zone of a regurgitant jet.  This was done by 
measuring the radius of the PISA shell from the left ventricular side, at an aliasing velocity of 40 
cm/s, and measuring the peak velocity of MR jet by CW. The figure 9 demonstrates PISA zone on the 
left and the measurement of MR peak velocity by CW doppler on the right.  Regurgitant volume (RV) 
we determined using the following  formula (212):  
RV = EROA x VTI,  
Where EROA is effective regurgitant orifice area and VTI is the velocity time integral of the mitral 
regurgitation jet.                                                                                                                                                                         
MR was graded as a mild, moderate, moderate to severe and severe valvular insufficiency based on 
the recommendations by the British Society of Echocardiography. Our focus of interest was a 
haemodynamically significant MR, where we included moderate, moderate to severe and severe 
valvular insufficiency.  Also a part of assessment was to determine whether MR was a primary or 




In cases with secondary MR,  we graded as a severe regurgitation when RV was > 30 ml, and EROA 
was > 0.2. Primary MR we graded as a mild when RV was < 30 ml and EROA < 0.2. The rest of the 
patients with values above these figures were graded as having the significant MR. 
As part of MR assessment we also measured MV annulus in the late diastole for every patient in 
parasternal long axis view (PLAX) and apical 2 chamber view (A2C) and determined whether or not 
our patients with significant MR were suitable for possible Mitral Clip based on the aetiology and 
morphology of the valvular insufficiency. 
 
Figure 10. Bi-plane Simpson`s method for LV EF calculation. 
2.4.3 Left ventricular (LV) systolic and diastolic function 
The left ventricular global systolic function was assessed by biplane Simpson`s method to determine 
ejection fraction (EF). This was done on-line while acquiring echo images. LV end systolic and end 
diastolic diameters and volumes had been measured as part of systolic function evaluation (Figure 
10). The left ventricular pressure rise (LV dP/dt) measurement in early systole was another way of 
evaluation of LV global systolic function. The regional wall motion abnormalities were identified 
visually. 
To assess LV diastolic function E, A waves and E/A ratio had been measured by pulse wave (PW), E` 





2.4.4 Right heart function 
The right ventricular (RV) function assessment in our patients was more challenging due to poorer 
visualisation of the right side of the heart compared to the left side and inability to apply 
quantitative biplane Simpson method. The right ventricular diastolic and systolic areas had been 
obtained with further calculation of the RV fractional area change (RVAFC), which was one of the 
main parameter in the assessment of RV systolic function (Figure 11). Other methods, which we 
applied for the right ventricle, were tricuspid annular plane systolic excursion (TAPSE), visual 
assessment of RV size and systolic function, RV Strain and Strain Rate. Basal RV diameter and TV 
annulus had been measured in the late diastole as part of right heart function assessment. 
 
                RV  END-DIASTOLE                                RV  END-SYSTOLE 
  
Figure 11. RV fractional area change 
The accuracy of RV systole durability was marked by measuring pulmonary valve opening and closing 
time. Then RV Strain and Strain Rate curves were obtained from basal, mid and apical segments of 
RV in apical 4 chamber view. Again the analysis has been done offline. 
2.4.5 Left and right atriums, other valvular functions  
Echocardiography study has been completed with comprehensive assessment of the rest of heart 
morphology and function. Left and right atrial areas, pulmonary artery pressure, tricuspid, 
pulmonary and aortic valve functions had been assessed. The tricuspid regurgitation (TR) was graded 
visually by Colour doppler as a mild, moderate, moderate to severe and severe valvular insufficiency. 
2.5. Statistical Analysis 
The optimum cut-off for prediction of 6-month mortality was estimated by identifying the sensitivity 
and specificity associated with the maximum Youden Index. These cut-offs were then used as a 
binary determinant of significant vs non-significant MR severity. 
Socio-demographic and baseline characteristics were summarised by severity group and overall for 
the complete analysis set. Categorical variables were reported as numbers and percentages and 
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between-groups comparisons compared using the chi-square test or Fisher’s exact test, as 
appropriate. Continuous variables were reported as means and standard deviations or as medians 
and interquartile ranges and compared using Student’s t test or the Mann-Whitney U test. 
For the primary analysis of 6-month mortality, unstratified Kaplan-Meier curves were constructed. 
Hazard ratios were estimated using an unadjusted Cox regression model, with statistical significance 
being assessed using the logrank test. Secondary analyses were carried out using Cox regression 
analyses adjusted for significant covariates. Selection of covariates to be included was based on 
initial multiple univariate regression analyses, modified according to clinical opinion from the 
research team. These were gender, age, body-mass index and pre-existing diagnoses of chronic 
obstructive pulmonary disorder, hypertension, chronic kidney disease, ischaemic heart disease, 
diabetes mellitus and cerebrovascular disease. For all comparisons, the threshold of statistical 
significance was set at a 2-sided α-value of 0.05. 
2.6 Data storage 
Enrolled patients had objective, echocardiographic and clinical characteristics collected via a 
standardised collection form which was stored online in a password-protected database specifically 
devised for study by Metanoic Health Ltd, United Kingdom.   
Data was entered by primary operators and double checked by independent specialists. Histograms 
were performed on all continuous data to screen for statistical outliers using Statistical Package for 
the Social Sciences (SPSS) version 24 (IBM, USA). Any outlying data points were then rechecked to 
screen for input errors or errors of measurement.  The echocardiography data was retained on two 
separate hard-drives to allow for off-site analysis and to reduce the risk of data loss in accordance 
with Good Clinical Practice research protocols. 












CHAPTER 3. RESULTS 
3.1 Left ventricular (LV) geometry, cardiac function and prognosis in 
patients with significant mitral regurgitation (MR) 
3.1.1 Background 
Mitral regurgitation (MR) is one of the most common valvular heart disorders, with an 
estimated worldwide prevalence more than five million which increases with age (144). MR 
is classified as primary (also known as organic) when principally due to a structural or 
degenerative abnormality of the mitral valve (MV) apparatus with deficiencies of function 
either leaflets, chordae tendineae or papillary muscles. Secondary (also known as functional) 
MR occurs in the absence of organic MV disease, usually from left ventricular (LV) 
remodelling and/or dysfunction.  Secondary MR is more common than primary MR (22) and 
associated with a worse prognosis (compounded by the underlying cardiomyopathy). In 
latter in contrast to primary MR the benefits of MV surgery are uncertain.  
A strong association between secondary MR severity and both all-cause mortality and heart 
failure hospitalisations has been reported (22). 
3.1.2 Study results. Total number of recruited patients. Exclusions 
616 consecutive patients presenting with symptoms of acute or exacerbation of CHF were 
assessed for eligibility for the MRAHF study from July 2016 to August 2017. We included 447 
(72.6%) patients into the analysis out of 500 patients recruited in total. 53 patients have 
been excluded due to the variety of reasons such as poor echo windows,  incomplete study, 
terminal stage of disease when echo was not feasible or when they did not meet inclusion 
criteria into the study, BNP was ≤ 100 pg/ml,  the late recruitment,  etc.  
418 individuals were included in final analysis after excluding the data from rehospitalisation 
and three individuals lost to follow-up. 
3.1.3 Technically difficult cases 
Combination of qualitative, semi quantitative and quantitative analysis was used for 
assessment of MR. We were not able to quantify MR in 97 cases due to lack of CW/colour 
signal or eccentric nature of MR jet. However, all of them had sufficient echo image quality 
to allow either semi-quantitative or qualitative  assessment of MR severity. So, amongst  
them visually 94 patients had mild MR,  1  - moderate,  1- moderate to severe and  1 - severe 
MR. 
3.1.4 Mortality data 
6 months outcome was available for 445 patients.  2 patients were not UK residents and left 
the country earlier. 6-months mortality for the whole cohort was 28%. 
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3.1.5 Group division 
All our patients (100%) had some degree of MR. They were divided into 2 groups depending 
on MR severity. The control group of patients with mild MR included 253 patients (60.5%) 
and another group with significant MR -165 patients (39.5%) including moderate, moderate 
to severe and severe MRs. 
3.1.6 Primary & secondary MR 
The vast majority of patients with significant MR (154 patients, 93.3%) were secondary in 
origin, when regurgitation was due to LV cavity and/or mitral valve (MV) annular dilatation, 
papillary muscle displacement leading to poor leaflet tip coaptation. Small minority of 
patients (11 patients, 6.7%) had MR due to primary abnormality of MV apparatus itself. 
3.1.7 Baseline characteristics 
The baseline characteristics for the both 2 groups including age, gender, haemodynamics at 
admission, blood test results, comorbid conditions, ECG rhythm with QRS duration,  previous 
and current cardiology review  including previously performed echoes are shown 
below(TABLE 13, Appendix 8). 
TABLE 13. Baseline characteristics and observations of patients with mild and significant MR. 
 All patients 
(n = 418) 
Significant MR 
(n = 165) 
Mild MR  




























Race, n (%) 
   White 






















BMI, mean: kg/m2 (sd) 
 
Comorbidities n (%)  
   Coronary artery disease 
   Hypertension 
   Diabetes 
   Chronic Kidney Disease 
   COPD 





































     
Presentation 
NYHA class, n (%) 
    II 
    III 
    IV 
 
ECG findings 
   Sinus rhythm, n (%) 
   AF, n (%) 
   Paced, n (%) 
   Other rhythm, n (%) 
       
Observations 
BPs, mmHg mean (sd) 
BPd, mmHg mean (sd) 







































































Haemoglobin, g/L mean (sd) 
Creatinine, μmol/L mean (sd) 
eGFR, mL/min/1·73m2 mean (sd) 
CRP, mg/dL mean (sd) 






































BAME = Black, Asian and Minority Ethnic. COPD = Chronic Obstructive Pulmonary Disorder. NYHA = New York Heart Association. AF 
= Atrial Fibrillation. BPs = Blood Pressure systolic. BPd = Blood Pressure diastolic HR = Heart Rate. SpO2 = Peripheral Capillary Oxygen 
Saturation. eGFR = estimated Glomerular Filtration Rate. CRP = C-Reactive Protein. BNP = Brain Natriuretic Peptide.* p-values are 
estimated using Mann-Whitney U-test for medians, N-1 χ2 for proportions and independent samples t-test for continuous variables. 
 
There were no significant differences in a number of baseline characteristics for both of our HF 
patient groups with mild MR and significant MR (TABLE 13). There was, however, difference in 
patients’ BMI. Those with significant MR had lower systolic BP on admission, higher level of BNP and 
less likely to be in sinus rhythm. They also had broader QRS and more likely to be referred for 
cardiology review.  
 




LVEF 40 - 
49% 
LVEF 























(19.0%) 9 (37.5%) 
17 









(17.0%) 7 (11.1%) 4 (16.7%) 
10 
(12.8%) 21 (12.7%) 0.218 
ARNI, patients 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)   
Beta Blocker, patients 
    89 






(47.6%) 14 (58.3%) 
47 











(20.6%) 3 (12.5%) 
11 
(14.1%) 27 (16.4%) 0.352 
Digoxin, patients 
23 




(11.1%) 7 (11.1%) 2 (8.3%) 
12 











(49.2%) 12 (50.0%) 
46 
(59.0%) 89 (53.9%) 0.180 
Ivabradine, patients 1 (0.6%) 0 (0.0%) 1 (0.7%) 0 (0.0%) 1 (1.6%) 0 (0.0%) 1 (1.3%) 2 (1.2%) 0.081 
K/Mg supplements, 
patients 1 (0.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.3%) 1 (0.6%) 0.218 
MRA, patients 20 (11.9) 8 (8.2%) 
22 
(14.8%) 25 (9.9%) 8 (12.7%) 3 (12.5%) 
15 
(19.2%) 26 (15.8%) 0.081 
Vasodilator, patients 
24 






(15.9%) 2 (8.3%) 
11 
(14.1%) 23 (13.9%) 0.922 
 
 
      
The TABLE 16 shows the data on previous admissions taken from the notes or electronic records 
presented in preceding 12, 24 and 36 months for all cause and HF admissions to the SPH.  It 
demonstrates that there was no difference between all cause admissions between the groups in the 






































admissions for 12 
months 
309 128 240 414 89 46 132 267 <0.00001 
Total previous 
admissions for 24 
months 
466 191 372 632 138 74 190 402 <0.00001 
Total previous 
admissions for 36 
months 
610 260 483 848 190 89 234 513 <0.00001 
Previous admissions 
with HF for 12 
months 
82 22 66 83 20 17 51 88 0.0002 
Previous admissions 
with HF for 24 
months 
109 32 82 108 29 23 71 123 <0.00001 
Previous admissions 
with HF for 36 
months 
136 40 118 130 34 28 84 146 <0.00001 
First admission for 
HF in last 12 months, 
patients 
127 82 109 200 49 17 54 120 0.303 
Second admission 
for HF in last 12 
months, patients 
17 11 25 35 10 1 8 19 0.1738 
Third or later 
admission for HF in 
last 12 months, 
patients 
24 5 15 18 4 6 16 26 0.0053 
First admission for 
HF in last 36 months, 
patients 
111 72 101 188 44 12 41 97 0.0054 
Average length of 
previous hospital 
stay, days 
6.0 4.6 4.9 4.8 6.9 4.6 5.7 6.0 0.1683 
Maximum length of 
hospital stay, days 
90 41 53 53 90 15 46 90 - 






3.1.8 Echocardiography data 
Echo data in TABLE 17 shows haemodynamic parameters obtained during comprehensive bedside 
study. The full echocardiography study has been performed for every HF patients according to the 
standardised protocol designed for this study (Appendix 1). Quantitative offline analysis was 
performed on EchoPAC workstation (version 201, GE Vingmed Ultrasound). 













































































































5.2 ± 0.955 0.541 














4.2 ± 1.1 0.282 
LV EDV, ml 138 ± 56 112 ± 45 81.1 ± 38 99 ± 50 117 ± 50 127 ± 66 140 ± 61 129 ± 59 <0.0001 
LV ESV, ml 101 ± 51 62 ± 25 34 ± 17 58 ± 41 72 ± 38 86 ± 56 89 ± 56 82 ± 50 <0.0001 










70.3 (31.6) <0.0001 










44.7 (26.8) 0.0001 
LV EF, % 27.8 ± 8 45 ± 3 58 ± 6 45 ± 14 39 ± 13 35 ± 15 40 ± 15 39 ± 15 <0.0001 
































A wave 0.64 ± 0.81 ± 0.82 ± 0.81 ± 0.70 ± 0.65 ± 0.58 ± 0.63 ± 0.0001 
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0.325 0.334 0.393 0.373 0.371 0.432 0.232 0.314 






1.9 ± 1.13 2.2 ± 0.94 2.3 ± 1.26 2.1 ± 1.18 <0.0001 













































30.8 ± 8.9 29.9 ± 6.9 32.3 ± 8.5 31.4 ± 8.5 0.0001 
MV annulus, 
cm 






3.538 ± 0.6 3.762 ± 
0.6 
3.87 ± 0.5 3.85 ± 0.5 <0.0001 
RVAd, mm 22.17 ± 
8.99 





























39 ± 12 35.4 ± 13 30.7 ± 
10.9 










27 (42.9%) 15 (62.5%) 44 (56.4%) 86 (52.1%) 0.011 










































25.1 ± 8.8 27.3 ± 9.1 26.2 ± 9.8 26.0 ± 9.9 0.004 
TV annulus, 
cm 






3.78 ± 0.6 3.87 ± 0.8 3.81 ± 0.8 3.73 ± 0.8 0.01 
Systolic PAP, 
mmHg 
50.6 ± 17 53 ± 20 55.2 ± 19 50 ± 19 53 ± 16 55 ± 12 61 ± 20 57 ± 18 <0.0001 
Significant TR, 
number of pts 
(%, pts) 
85 (50%) 52 (53%) 78 (52%) 104 
(41%) 
40 (63%) 17 (71%) 55 (70%) 112 (68%) <0.0001 
Isolated LVSD 
(%, patients) 
168 (100%) 98 
(100%) 
0 (0.0%) 140 
(55.3%) 
46 (73%) 19 (79.2%) 62 (79.5%) 127 (77%) <0.0001 
Isolated RVSD 
(%, patients) 











91 (54.2%) 44 
(44.9%) 
0% (0) 56 
(22.1%) 































Those with significant MR had features of left ventricular remodelling with increase in end-diastolic 
(LVEDV)  and end systolic (LVESV)  volumes and reduction in LV ejection fraction (LVEF) in presence 
of significant volume overload (MR regurgitant volume) (TABLE 3). LA dilation was significant in 
group 2.  The changes in the right heart geometry and function were even more noticeable between 
the groups. The study showed that the severity of pulmonary hypertension (PHT) and right 
ventricular (RV) dysfunction were much worse in the presence of significant MR: there was more 
prominent rise in systolic pulmonary artery pressures (PAP) and reduced RV fractional area change 
(RVFAC). 
3.1.9 The right ventricular function in acute HF 
Patients with RV dysfunction as assessed by RVFAC (<32%) showed a significant excess of mortality 
(p ≤ 0.01), with a hazard ratio (HR) of 1.9 (95% CI 1.3-2.7, p<0.01) (TABLE 4, FIG 1). TAPSE – the 
universal marker of RV function assessment was not a significant predictor of mortality (p>0.2) and 
in fact was reduced in presence of moderate-severe tricuspid regurgitation (TR) (p<0.05). 
Pulmonary hypertension at rest was a strong predictor of all-cause mortality: SPAP ≥45mmHg was 
associated with a significant increase in mortality compared to those with <45mmHg (p= <0.00001) 
with a HR of 3.2 (95% CI 1.8-5.5, p<0.00001) (TABLE 18, FIG 12).  












Left Ventricular Failure (LVEF) 1.486 1.006-2.195 P <0.05 
Moderate-to-severe pulmonary 
hypertension 
3.151 1.791-5.545 P <0.00001 
Right Ventricular Failure (RV FAC) 1.747 1.191-2.564 P <0.01 
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FIGURE 12. Kaplan-Meier Survival distribution curves for categorised LVEF, RV FAC and SPAP. 
 
3.1.10 Mortality and prognosis 
For statistical comparison values were categorised and analysed using Chi-square testing. Kaplan-
Meier survival plots were created to demonstrate difference in survival. Independent T-tests were 
performed to demonstrate statistical difference in continuous data. 6 months mortality in presence 
of significant MR was 34.9%, in presence of mild MR was 23.8% with P value < 0.05 (FIGURE 13).  
 




Additionally, 198 patients (44.3%) with known history of MR prior to admission demonstrated 6 
months mortality to be 34.5% against 23.1% when MR was not known on admission with P value < 
0.05 (FIGURE 14). 
 
FIGURE 14. 6 months mortality -– 34.5% in patients with known MR & 23.1% when MR was not known 
3.1.11 Discussion 
In our study we aimed to find out whether severity of MR has an impact on hospital admission rate 
and prognosis of patients with heart failure. It is not well studied if MR could trigger hospital 
admission with HF. MRAHF study has demonstrated the prevalence of MR and TR in patients with 
acute HF and demonstrated importance of right heart dysfunction in short term prognosis. 
There was high prevalence of patients with significant MR (39.5%). These patients have number of 
important characteristics which were different to those who did not have additional effect of volume 
overload. Amongst important baseline characteristics amongst MRAHF patients there was significant 
difference in the level of B-type natriuretic peptide (BNP) as an indicator of severity of HF between 
mild and significant MR patient groups.  The patients with significant MR had higher number of BNP 
level and they were more likely to have previous admissions with HF.  
BNP has been proven to be a useful diagnostic marker of severity of HF and a valuable prognostic 
predictor (213). BNP is secreted by the left ventricular myocardium in response to hemodynamic 
stimuli such as ventricular volume expansion and pressure overload (214). Initially it is released as a 
proBNP into the circulatory system and after it is cleaved into the biologically active C-terminal of 
BNP and the biologically inactive, NT-proBNP. ProBNP is primarily synthesized and released in the 
ventricle in response to ventricular hemodynamic changes; therefore, it can reflect ventricular 
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dysfunction better than other natriuretic peptides (NPs) (215). Moreover, it is also known to cause 
strong vascular relaxation and natriuresis.  
Another significant difference between the groups was in patients` BMI. This might be also the 
results of more advanced HF. Cachexia is a prevalent pathological condition associated with chronic 
heart failure. Its occurrence predicts increased morbidity and mortality independent of important 
clinical variables such as age, ventricular function, or heart failure functional class (216). The clinical 
consequences of cachexia are dependent on both weight loss and systemic inflammation. It is a 
multifactorial condition where underlying pathophysiological mechanisms are not completely 
understood making it difficult to develop specific prevention and treatment therapies (216). Our 
patients with significant MR were not extremely cachectic, however, they were significantly lighter 
in weight. 
ECG findings on admissions demonstrated tendency to broader QRS and arrhythmias in these 
patients. There is a sinister synergism between atrial fibrillation and heart failure. These common 
cardiovascular conditions often co-exist and result in significant morbidity and mortality (217). The 
increased propensity for AF in HF can be explained by structural and electrophysiological atrial 
remodelling that creates an environment favourable to the development and maintenance of AF 
(217). Patients with HF and history of atrial arrhythmias exhibit atrial enlargement, loss of 
functioning atrial myocardium and impaired atrial conduction, which lead to increased inducibility 
and sustainability of AF (218). Indeed, patients with significant MR had larger LA size (TABLE 17). 
Pressure or volume overload of the atria causes elongation of the cardiomyocytes, i.e. increased 
stretch. Stretch of the atria is a main contributor to atrial remodelling. These changes occur in atria 
in patients with heart failure, hypertension, and mitral valve disease prior to clinical presentation 
with AF (219,220), as such creating a substrate for AF. It is thought that once AF develops the 
remodelling process deteriorates further (221,222). Thus, atrial remodelling in patients with AF is 
caused by both the associated diseases and AF itself. 
It has also been reported that prolongation of QRS (> or =120 ms) occurs in 14% to 47% of HF 
patients and predisposes this population to an increased risk of ventricular tachyarrhythmias (223). 
The study showed that most of the HF patients have secondary MR rather than primary. It is known 
that the secondary MR develops as a consequence of LV remodelling, which was clearly evident in 
patients with significant MR. Interestingly, LV volumes in the group 2 (significant MR group) were 
within the normal range accepted by current international and national guidelines (76,224,225), but 
significantly increased when compared with those without significant MR. Beyond LV volumes, the 
pattern of LV remodelling was recently shown to carry additional predictive value for vascular and 
heart failure-related events (226). These findings support the hypothesis that the linkage between 
LV remodelling and outcome occurs not merely through the adverse impact of cardiac pathology per 
se, but also via the role of LV morphologic change as a measure of concomitant vascular pathology 
(226). 
Both groups had significant pulmonary hypertension, but in patients with significant MR the severity 
of PHT was more prominent. Pulmonary hypertension in HF is thought to result from congestion and 
chronic pulmonary venous hypertension. It may initially begin as a passive process resulting from 
congestion and elevated filling pressures, and pulmonary venous hypertension. With chronic 
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congestion, pulmonary vascular tone may become irreversibly elevated (227). However, the 
fundamental mechanisms determining pulmonary vascular responses in response to heart failure 
and the development of PH remain incompletely understood. There is an evidence that pulmonary 
hypertension is associated with a negative impact on survival (228). 
It is known that RV function is difficult to assess due to its unusual crescent shape, the irregular 
endocardial surface and complex contraction mechanism; the RV free wall is more difficult for 
visualisation on echocardiography compared to the rest of the heart (80,229). However, the 
introduction of new modern ultrasound machines with improvements in image quality and imaging 
modalities has made it possible to use echocardiography as a first line modality to assess the 
structure and function of the right heart (230,231). The technique of how we measured RV function 
(RV FAC) is shown in FIGURE 15. 
FIGURE 15. RV fractional area change is shown with end-diastolic and end-systolic areas. 
 
FIGURE 16. TAPSE for an assessment of RV systolic function. 
 
Tricuspid annular plane systolic excursion (TAPSE) is normally widely used for RV systolic function 
assessment on echocardiography, probably due to the simplicity of the method (FIGURE 5). To 
assess RV function by TAPSE, M-mode is placed on RV free wall across TV annulus level in four 
chamber view. The level of TV annulus systolic excursion is believed to assess reliably RV longitudinal 
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systolic function (230-232). Limitations include load and angle dependence, as well as the potential 
influence of the functional status of the left ventricle. Moreover, this measure does not take into 
account the contribution of the ventricular septum and/or the right ventricular outflow tract to right 
ventricular performance. (230,233) 
RV systolic function assessment for both radial and longitudinal function in one plane view is called 
RV fractional area change (RV FAC). It is more time consuming method than TAPSE and calculated by 
difference between end diastolic area and end systolic area divided by end diastolic area (234) 
(FIGURE 15, 16).  
MRAHF study showed that RV FAC as a marker of RV systolic function proved to be more sensitive in 
predicting outcome rather than TAPSE. Also there is data, which showed that the fractional area 
change has been found to correlate with magnetic resonance-derived right ventricular ejection 
fraction, as well as to predict outcome in adult patients with myocardial infarction and pulmonary 
hypertension (235,236). Similar data does not apply for TAPSE.  
RV FAC was lower in presence of significant MR and associated with visually enlarged RV.  
Patients with mild and significant MR did not differ in all cause hospital admissions, but significant 
MR patients had more HF admissions in the last 24-36 months. It is not surprising to find that 
presence of more advanced HF reflected by higher BNP level and cardiac remodelling led to higher 
rate of previous admissions with HF. MRAHF is compatible with other studies (22), which proved 
that the development of significant MR in patients with HF is strongly associated with poor 
prognosis. In the study from the Duke Cardiovascular databank, which included 2,057 HF patients 
with an LVEF < 40%, qualitative assessment on left ventriculography showed 29.8% patients had 
moderate to severe and severe MR and it was an independent predictor of 5 year mortality (237). 
Another study from Mayo clinic included 1,256 patients with dilated cardiomyopathy and the 
percentage of severe MR in this cohort of HF patients was 24 %. It was an independent predictor of 
death or HF hospitalisation during 2.5 years of follow-up (161). 
There were a few limitations in our study. One of this is a disadvantage of bedside echocardiography 
over departmental study. A portable machine, patients` acuity and time limit – all these factors were 
affecting on the quality and completeness of the study. As part of MRAHF trial protocol echo was 
done within 48 hours of hospital admission. This was the time when HF patients were more poorly 
and less able to cooperate due to their haemodynamic instability. For example, some patients found 
it difficult to remain in left lateral decubitus position for the entire time of echo scan considering 
that the time required to complete a full echo protocol was between 45 minutes to 1 hour. As a 
result, some images had respiratory artefacts and did not have fine tuning of scale and ECG traces. In 
some case the test was foreshortened. This was the reason why we had a few incomplete studies. 
Performing echoes on the ward was also challenging due to space availability, noise level and bright 
lighting. The beds did not have ergonomic features of echo couches which made maintaining 
posture for operators difficult. 
Another potential limitation was the fact that MRAHF was a single centre study with data specific to 
local area. It is difficult to extrapolate with data worldwide without some corrections where 
demographics and co-morbid conditions could be different.     
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MRAHF was an observational study, a longitudinal follow up is needed, particularly in mild MR group 
to see, if MR is a result of progressive LV dilatation or other factors cause simultaneous LV dilatation 
and MR. 
The current literature on MR highlights a strong association between a severity of MR and mortality 
with HF (22). Few studies have demonstrated that significant MR was an independent predictor of 
death and HF hospitalisation (161,238,239).   
Summary: MRAHF study showed the patients with significant MR presented with higher 6 months 
mortality in comparison with the group of patients with mild MR. Also, when MR was known on 
admission, these patients had poorer outcome than HF patients without known MR on admission. 
These findings of our study proves how much the presence of significant MR, if not treated 
effectively, can quickly lead to HF progression to higher stage of the disease and poor outcome.  
3.2 The effect of use of National Institute for Health and Care Excellence 
(NICE) guidelines on outcome in MRAHF patients. 
3.2.1 Background 
The NICE guidelines for HF offers best practice advice on the care of people with acute heart failure 
and covers important aspects of the diagnosis and evidence based recommendations on 
management of this condition (NICE 2014) (240).  
In brief, in patients presenting with new suspected acute heart failure, the NICE guidelines 
recommends to start with taking detailed history and clinical examination, perform standard 
investigations – for example, electrocardiography, chest X‑ray and blood tests to confirm the 
presence of heart failure. In people presenting with new suspected acute heart failure, a single 
measurement of serum natriuretic peptides (B‑type natriuretic peptide [BNP] or N‑terminal 
pro‑B‑type natriuretic peptide [NT‑proBNP]) is advised using the following thresholds to rule out the 
diagnosis of heart failure: BNP less than 100 ng/litre or NT‑proBNP less than 300 ng/litre. With new 
suspected acute heart failure and raised natriuretic peptide levels transthoracic Doppler 2D 
echocardiography should be performed to establish the presence or absence of cardiac 
abnormalities(240). 
Patients with suspected heart failure and previous myocardial infarction (MI) should be referred 
urgently to have transthoracic Doppler 2D echocardiography and specialist assessment. 
Transthoracic Doppler 2D echocardiography needs to be performed within 48 hours of admission 
and review by cardiologist within 24 hours of their admission to a hospital (241). 
3.2.2 Study results 
The research team of MRAHF study has followed strict international guidelines to identify patients 
with acute HF (FIGURE 6). We have used point of care BNP device in triaging patients (i-STAT 1 
Analyzer “Immuno-Ready”), which is in-vitro diagnostic test for bedside measurement of BNP in 
plasma samples using EDTA as the anticoagulant.   
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FIGURE 17. Diagnostic algorithm for patients with suspected AHF; AF: atrial fibrillation, SVT: supraventricular 
tachycardia, VT: ventricular tachycardia, VEs: ventricular extrasystoles, BNP: brain natriuretic peptide, TTE: transthoracic 
echocardiogram. 
 
The clinical team was blind to the results of research bedside BNP. The inpatient practice at St 
Peter’s hospital does not allow to receive the results of blood test for BNP within 24 hours. We have 
therefore modified the NICE guidelines and used cardiology review within 24 hours as equivalent of 
NICE recommended pathway (FIGURE 18). It demonstrates the decision tree is based on NICE 
recommendations. In inpatient clinical practice at St Peter’s hospital BNP test is not performed 
routinely for HF patients before cardiology review. Therefore, referrals to cardiology is based on 
clinical assessment without prior specific blood tests. The FIGURE 19 demonstrates the sequence of 
specialist review and a number of tests received by HF patients after they had been admitted to a 
hospital. 
The patients have been divided into 2 groups (TABLE 18).  In group 1, which was seen by a 
cardiologist within 24 hours, there were 204 patients (45.6% from the whole cohort of MRAHF 
population). Out of 253 patients (57%) with no cardiologist review on admission, 32 patients (Group 
2 A) were referred to cardiology review after 24hours (7.6%). The rest of the patients (Group 2B) 
were not seen by a cardiologist during entire length of admission 221 patients (49.4%). 
The main demographic and clinical data is presented in TABLE 18. Patients who were not seen by 







TABLE 18. Demographics and haemodynamics.  
 Group 1 
(Cardiology 
review in 24 
hours) 









Total number of 
patients, % 
196 (46.9%) 30 (7.1%) 192 (45.9 %) < 0.0001/0.765 
Mean age, years 75.73 ± 12.5 75.3 ± 
11.9 
82.8 ± 9 0.856/< 0.0001 
Gender, males 123 (60.3%) 19 
(59.4%) 
92 (43.6%) 0.923/0.0007 
BMI 28.7 ± 7.2 30.5 ± 7.2 28.4 ± 8.9 0.189/0.71 
BP systolic, 
mmHg 
135.6 ± 26.9 133.2 ± 
25.6 
136.8 ± 25.8 0.637/0.64 
BP diastolic, 
mmHg 
76.7 ± 17.5 75.8 ± 
17.8 
74.1 ± 16.2 0.788/0.117 
HR, bpm 92.7 ± 30.2 92.0 ± 
32.9 
92.6 ± 28.3 0.904/0.97 
BNP, pg/ml 1146 ± 999 1372 ± 
980.9 
1212 ± 1015 0.234/0.50 
Hb, g/L 124.5 ± 22.5 129.2 ± 
21.7 
118.6 ± 20 0.271/0.005 
WBC, x10⁹/L 10 ± 9.9 8.9 ± 2.8 8.8 ± 5.7 0.534/0.129 
CRP mg/dL 33.8 ± 45.6 49.8 ± 
61.7 
39.0 ± 43.6 0.081/0.267 
eGFR, 
mL/min/1.73m2 
38.8 ± 13 43.8 ± 
12.2 
38.4 ± 13.0 0.043/0.754 
CKD, number of 
patients 
88 (43.1%) 13 (40.6%) 107 (50.7%) 0.79/0.121 
Known CAD,       
number of 
patients 
78 (38.2%) 11 (34.4%) 80 (37.9%) 0.681/0.949 
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HTN,                  
number of 
patients 
106 (52 %) 20 (62.5%) 120 (56.9%) 0.269/0.317 
COPD,               
number of 
patients                            
12 (5.9%) 6 (18.8%) 46 (21.8%) 0.11/<0.0001 
CVA,                  
number of 
patients 
31 (15.2%) 2 (6.3%) 36 (17.1%) 0.178/0.599 
DM type 2,                 
number of 
patients 
70 (34.3%) 10 (31.3%) 61 (28.9%) 0.739/0.237 
ECG, sinus 
rhythm 
90 (44.1%) 13 (40.6%) 75 (35.5%) 0.711/0.074 
ECG, AF 83 (40.7%) 13 (40.6%) 106 (50.2%) 0.992/0.052 
ECG, other 
rhythm 




113.9 ± 32 109.1 ± 
34.1 
106.3 ± 32.7 0.435/0.017 
 
The echo data showed lower LVEF in the group seen by a cardiologist (TABLE 19). LVEF in the group 1 
was 40.7%, in the group 2A was 40.1% (P = 0.84), in the group 2B – 45.7% (P = 0.0006). There were 
features of LV remodelling in group 1 and 2A compared to the group 2B (116.6 ml & 146.6 ml vs 99 
ml, P 0.005/0.0004). There was higher prevalence of significant MR in patients seen by cardiologist 
(53.3%), whereas prevalence of RV dysfunction was higher in patients not seen by specialists 
(67.3%). Also, PAP was higher and the prevalence of significant TR was higher in the group 2B. 
TABLE 19. Comparison of ECHO data. 
 Group 1 Group 2A Group 2B P value 
LV EF, % 40.7 %  40.1 % 45.7 % 0.84/0.0006 
Mean LV EDV 116.6 ml 146 ml 99 ml 0.005/0.0004 
Mean RV FAC 37.6 % 33.3 % 36.8 % 0.08/0.514 
Systolic PAP 50.6 mmHg 50.8 mmHg 55.7 mmHg 0.95/0.007 
                                     
Mild MR 
                                       
42.7 % (108 pts) 
                  
6.7 % (17 pts) 
                  
50.6 %     
(128 pts) 
                        
0.043/0.114 
                                                                                                                                     
69 
 
Significant MR 53.3 % (88 pts) 7.9 % (13 pts) 38.8 %        
(64 pts) 
0.024/0.15 
                                     
Mild TR 
                                        
46.8 % (101 pts) 
                  
9.7 % (21 pts) 
                  
43.5 %        
(94 pts) 
              
0.0017/0.645 
                         
Significant TR 
                                      
44.3 % (102 pts) 
                   
4.8 % (11 pts) 
              
50.9% 
(117pts) 





                                         
47.9 % (69 pts) 
              
11.8 %          
(17 pts) 
                  
40.3 %        
(58 pts) 
          
0.007/0.39 
                                 
Isolated LVSD 
                                        
51.3 % (78 pts) 
                 
3.3 %              
(5 pts) 
                 
45.4 %       
(69 pts) 
                                       
0.039/0.477 
                                 
Isolated RVSD 
                                        
26.5 % (13 pts) 
                  
6.1 %  (3 pts)                     
                 
67.3 %        
(33 pts)        
                                     
0.46/0.013 
      
6 months mortality in the group 1 is 16.7% (34 patients), in the group 2 – 37.4% (91 patients), P 
value = 0.0001. No 6 months mortality data was available for 3 patients. 
19.6% (40 patients) died within 1 year from the group 1, from the group 2 – 41.98% (102 patients) 
within the same period of time, P value < 0.0001. No mortality data was available for 122 patients.  
As shown above patients with significant MR were more likely to be seen by a cardiologist, however 
a large proportion did not benefit from cardiology input (TABLE 20), 41.8% of such patients did not 
have echo on this admission, while more than 57.6% of them had echo previously within 36 months. 
Nearly half of the patients had echo within 48 hours (53%) with no significant difference between 
the groups with mild and significant MR . 
 
TABLE 20. The number of MRAHF patients meeting NICE guidelines requirements for cardiologist review and 
transthoracic echocardiography on admission. 




within 24 hours,    
number of patients 
(NICE guidelines 
recommendations)  
108 (42.7%) 88 (53.3%) 196 (46.9%) 
GROUP 2 A -
Cardiologist review 
later than 24 hours, 
17 (6.7%) 13 (7.9%) 30 (7.1%) 
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number of patients 
GROUP 2 B -            
Did not have 
cardiologist review, 
number of patients 
128 (50.6%) 64 (38.8%) 192 (45.9%) 
Echocardiography 
within 48 hours, 
number of patients 
(NICE guidelines 
recommendations) 
145 (57.3%) 87 (52.7%) 232 (53.2%) 
Echocardiography 
later than 48 hours, 
number of patients 
12 (4.7%) 9 (5.5%) 21 (5.1%) 
Did not have 
echocardiography, 
number of patients 
95 (37.5%) 69 (41.8%) 164 (41.6%) 
Previous 
echocardiography 
144 (56.9%) 95 (57.6%) 239 (57.2%) 
No ECHO on current 
admission, but had 
ECHO before 















FIGURE 18. Decision tree for acute heart failure, initial management (NICE guidelines 2014). 
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FIGURE 19. Decision tree for acute heart failure at St Peter`s Hospital. 
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It was not possible to use exact NICE guidelines pathway due to local practice. Although all MRAHF 
patients had BNP test done as part of the recruitment process, clinical team was blind to the results, 
therefore we used cardiology review as an optimal substitute.  
Clinical team have identified a large number of HF patients, however we have found out that slightly 
more than half of the MRAHF patients did not have cardiology review within 24 hours of admission. 
This is not surprising given modern complexity of patients with multiple comorbidities when HF was 
not always the straightforward diagnosis. Taking into consideration all challenges which presented 
to the clinical team, especially during acute on-call periods with large number of patients attending 
A&E and acute medical unit, the number of identified HF patients is still impressive. 
Acute Heart failure 
(HF) patients admitted 
























The main focus of referral to cardiology appears to be on LV function and dilatation, whereas RV 
geometry and function is overlooked. The majority of patients from the group 2 (73.4%) had an 
isolated RV dysfunction. This might be driven by the fact that current guidelines are focused on LV 
function (19).  Most of worldwide used HF classifications are based on LV EF, including the latest ESC 
guidelines with HFpEF, HFmEF and HFrEF. It is historical that grading of HF was focusing on LV 
contractile function. 
The cardiology review had a significant impact on patients` outcome. The patients who did not have 
cardiology review within 24 hours had significantly poorer outcome and a higher 6 months and 1 
year mortality rate in comparison to group reviewed by the specialist team within above mentioned 
time limit. There are no similar to MRAHF trials have been found to compare with, however, there 
are number of trials have been done, which investigated the role of specialized multidisciplinary 
team involvement (either in a clinic or a non-clinic setting) in HF patients` follow up and it showed 
that this strategy has reduced mortality, HF hospitalisations, all cause hospitalisations and appeared 
to be cost saving (242). 
This data needs to be interpreted with caveat of age difference between the groups. It is not clear if 
referring team and triaging by cardiologist left elderly patients to be managed by general physicians.  
There are trials, which demonstrated that elderly patients hospitalised with HF have poor prognosis, 
particularly if their heart failure symptoms are caused by LV systolic dysfunction. In general, the 
most of HF patients (up to 80%) are known to be elderly (243). When compared with younger 
patients, the elderly population has a multiple comorbidities (hypertension, atrial fibrillation, 
peripheral vascular disease and coronary artery disease, valvular disease and kidney failure or 
anaemia) and polypharmacy (243).  
There is also gender difference in triaging of HF patients for cardiology review, less female patients 
had cardiology review. It is difficult to explain this kind of phenomenon, but it is obvious that in 
females it has appeared that diagnosis of HF could be more challenging. It is known that females 
have better survival in HF (244,245), mainly due to less prevalence of ischaemic cardiomyopathy. 
They tend to have higher rate of depression (246) and different co-morbid presentation (244,245) 
which might be reason of referral to other specialist groups. There is reported disparity of care in 
literature. It has been reported that females receive less invasive treatments and prone to be 
subscribed less evidence based medical therapy (245,247,248). 
In summary, implementation of NICE guidelines in full to complement clinical assessment is likely to 
improve specialist input in managing AHF patients and therefore short and long term outcomes. The 
bedside BNP is a feasible replacement option to laboratory defined BNP in acute emergency room. 
Use of point of care bedside BNP by research team proved it be simple and strait forward procedure 






3.3 Economic impact of HF admissions and length of stay on the hospital    
budget 
3.3.1 Background 
The burden of patients with heart failure on health care systems is widely recognised with estimated  
HF expenditure accounted for 1.2% of National Health Service (NHS) budget in the United Kingdom 
(UK) (189). Subsequent studies in other countries reached similar results  (13-15) with some 
individual patterns of care and differences in health service related to age, socio-economic factors 
and the presence of co-morbidities in different countries. 
3.3.2 Study results 
We asked our Financial department at St Peter`s Hospital to provide us with the list of HF patients 
admitted to the trust during the period of recruitment process for MRAHF study. Overall, there were 
951 patients who had HF as part of clinical diagnosis identified by coding process which is likely to 
represent all cause admissions with HF (TABLE 21). The total expenditure and average cost are given 
in TABLE 22. For the period from 4/07/2016 until 13/09/2017 the total costs for HF patients spent in 
St Peter`s Hospital was £ 2,144,267 with average cost per patient £2,255.00. 
 
TABLE 21. HF patients admitted to St Peter`s Hospital (SPH) (Finance department data). 
Period  Number  of       
  Patients  
 Sum of Total         
 Expenditure  
 Average Cost  
  per patient 
2016/17          570  1,257,919               2,207  
2017/18         381  886,348               2,326  
Grand Total         951  2,144,267               2,255  
 
219 (49%) patients from our MRAHF dataset had missed diagnosis of HF by the coding team.  The 
distribution of missed diagnosis was slightly prevalent in patients with mild MR (P = 0.099). 
TABLE 22. Missed diagnosis of HF by coding team. 
 Mild MR Significant MR P< 







The rest of the MRAHF patients registered by the coding team had significantly higher average 
inpatient cost during this admission when compared to the average cost of HF admission. There was 
75 
 
no significant difference between patients with different severity of MR, probably the fact  driven by 
presence of multiple adverse haemodynamic factors such as LV and/or RV systolic dysfunction (table 
23). Similarly to RV FAC, presence of significant TR in isolation could not explain high cost of isolated 
RVSD which appear to bear highest financial burden in our cohort of patients. 
TABLE 23. Cost of index admissions of MRAHF patients. 
 Average cost per 
admission (£) 
Max cost per 
admission (£) 
Min cost per 
admission (£) 
P value        
(comparison made 
with average cost per 
patient, Finance dep. 




2255 ± 2858 24267 46 _______ 
Mild MR 3589 ± 3368 17269 199 < 0.0001 
Significant MR  3458 ± 3179 13995 342 < 0.0001 
Fractional area 
change > 32% 
3596 ± 3529 17269 199 < 0.0001 
Fractional area 
change < 32% 
3458 ± 2954 12985 219 < 0.0001 
Isolated LVSD           3251 ± 3307 17269 199 0.0001 
Isolated RVSD           4355 ± 3648 12985 532 < 0.0001 
Bi-ventricular 
dysfunction 
3570 ± 2854 12653 219 < 0.0001 
Significant TR 3637 ± 3271 16364 199 < 0.0001 
 
The TABLE 24 demonstrates the maximum number of recurrent admissions for all cause and heart 
failure for previous 12, 24 and 36 months with calculated on available cost data from index 
admission. 
Using average cost of HF admission we have calculated the approximate cost of previous hospital 
admissions for MRAHF population, 350 of them had previous all cause admissions in the preceding 3 
years with maximum up to 45 admissions for a single person. 217 patients with mild MR had at least 
1 admission, which was 80.1% from this group. 133 patients (75.6%) with significant MR also had 
repeatedly been admitted during the same period of time. 
83 patients (30.6%) with mild MR had been admitted with HF (primary or exacerbation of chronic) 
whereas 77 patients (43.7%) with significant MR had admissions with HF for the same period.  
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TABLE 24. Recurrent admissions with cost in patients with HF. 





















Previous all cause admissions 
per person for 12 months 
27 £ 96,903 8 £27,664 
Previous all cause admissions 
per person for 24 months 
38 £136,382 16 £55,328 
Previous all cause admissions 
per person for 36 months 
45 £161,505 18 £62,244 
Previous HF admissions per 
person for 12 months 
6 £21,534 5 £17,290 
Previous HF admissions per 
person for 24 months 
7 £25,123 6 £20,748 
Previous HF admissions per 
person for 36 months 
11 £39,479 7 £24,206 
 
The length of stay of previous admissions in mild MR group was 7.7 days on average with maximum 
up to 53 days and minimum of 1 day . Patients with significant MR had the average length of hospital 
stay 9 days with the maximum of 90 days and minimum of 1 day. Unfortunately, we were unable to 
calculate the effect of prolong hospital stay on the increase of cost due to complicated scheme of 
financial aspect and absence of pure HF one day hospital stay tariff.  
                                                                         
3.3.3 Discussion 
MRAHF study has aimed to investigate the financial aspect of hospital admissions with acute heart 
failure. There are very scarce number of studies, which have investigated financial aspect of HF. 
Amongst them are ADHERE registry(249) in USA, the EuroHeart Failure Survey(209) in Europe. 
The HF population is prone to have recurrent hospital admissions with further increase of cost for 
patients care. This is why HF patients are heavy burden for a hospital budget and healthcare in 
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general. According to the NICE data, approximately 67,000 people with acute heart failure were 
admitted into hospital in England in 2012/13 (190). 
The list of HF patients provided by SPH Finance department disclosed difficulties in accurate 
capturing of the data related to acute HF admissions. There were a number of MRAHF patients, who 
were missed from the Finance department list. This means that those 219 patients with acute HF did 
not get appropriate reimbursement for HF to reflect complexity of the ongoing disease. The minimal 
cost implication based on our calculations is 219 x £2,255.00 (£493,845.00). The average cost of AHF 
from our cohort suggests that assessment might be grossly underestimating the true costs. We can 
speculate, that this omission was caused by lack of universal parameter which could be used by 
coding team to help them navigate in complex discharge letters. 
As discussed in the previous chapter, bedside BNP could be used both as clinical and coding triaging 
marker. The cost of bed-side BNP cartridges is £ 28 per unit at the time of writing this thesis. If used 
routinely for patients suspected for HF using algorithm suggested by our research project to avoid 
overuse, bedside BNP, could have led to appropriate coding and reimbursement. Such testing may 
reduce up-front demand for echocardiography by modifying priority referral pathway for inpatient 
echocardiography (240). 
Patients with mild MR and significant MR did not have any significant difference in average cost at 
index admission but both had considerably higher in comparison with an average cost of patients 
without acute HF. Interestingly, MRAHF study showed that patients with isolated RVSD were more 
expensive in hospital management. Partly, it is explained by the fact that right heart 
decompensation is the terminal haemodynamic response in failing heart (234-236). Most 
importantly this might reflect lack of clinical focus on parameters of RV function (250-252). Even in 
research the focus is mainly on LV function. Routine PubMed search using the key words ‘AHF’, and 
LV function vs RV function brings 1281 papers on LV dysfunction vs 338 ones for RV dysfunction. 
Given the important prognostic implication of RVSD showed in the previous chapter it is of particular 
importance to improve our knowledge how to detect and address RV dysfunction as early as 
possible. 
The length of hospital stay (LOS) on index admission was considerably shorter when compared to 
other studies. MRAHF patients had average LOS of 2.3 days compared to the USA (4.3 days in the 
ADHERE registry (253)) and to Europe (average 11 days in the Euro-Heart Failure Survey (16)). This 
encouraging data should however be checked against readmission rate as there is a suggestion that 
the HF patients who are discharged early, tend to have high rate of readmissions (254) and this 
tendency could make cost even higher that it was expected. The limitation of our study is that 
previous admissions data is retrospective and does not allow to follow natural history of de novo 
AHF patients. Nevertheless, it demonstrated that patients with significant MR tend to have higher 
rate of pure HF admissions with significant price tag attached to such admissions.  
In summary, there is large number of AHF patients not identified by coding team. The cause is not 
entirely clear, but we suspect lack of single markers might be a large contributing factor in complex 
bouquet of comorbidities presented in discharge letters. Bedside BNP is a feasible and easy to use 
practical test in hands of clinicians with appropriate screening to avoid overuse. It can be used both 
78 
 
for improving triaging of AHF patients and appropriate capture of such admission by coding team. 
RVSD is the most expensive haemodynamic decompensation to treat and a low of clinical and 
research attention is needed for early recognition of RV failure.      
We propose to use the combination of BNP and Echo data (SPAP) to be used as indicators of HF 



























Heart failure is associated with high frequency of recurrent hospital admissions and high mortality, 
which leads to a significant economic burden on the UK NHS budget and other western healthcare 
systems. This is expected to increase further in the future due to the ageing population and increase 
in complexity of comorbid conditions (255). Cost of hospitalisations is responsible for the largest part 
of treatment costs and, thus, remains the main target for strategies aiming at cost reduction (255). 
Mitral regurgitation is a highly prevalent valvular disease. The development of secondary mitral 
regurgitation (MR) due to left ventricular dysfunction is strongly associated with a poor prognosis in 
patients with heart failure (22). The mechanisms underlying secondary MR are multifactorial (22). 
The prognostic implications of severe organic MR are well known and studied with the prevalence of 
MR increasing with age in general population (159,161,239). Overall, high cardiac event rates 
including HF are associated with severity of MR, which is also predictive of mortality (159,160). It is, 
however, unclear whether severe MR plays major role in acute exacerbation of HF requiring 
hospitalisation. 
According to the European Society of Cardiology the upper limit of normal BNP in the non-acute 
setting should be 35 pg/mL and in the acute setting, higher values of BNP should be used  (> 100 
pg/mL) (1).  We used BNP test to rule out HF, not for diagnosing it (1). The cut off 100 pg/ml was 
used for our patients to prevent missing of HF patients. 
4.2 Aims 
The one of the aims of MRAHF trial was to study prevalence of significant MR in HF patients 
admitted acutely to the hospital, its effect on the LV and RV geometry and function, and patients` 
prognosis. It was aimed to assess significance of the financial burden of HF patients with their 
recurrent admissions in a single district hospital like the SPH. It also was looked,  if  NICE 
recommendations for AHF managements were in use in this centre. 
4.3.1 Left ventricular geometry, cardiac function, haemodynamics and 
prognosis in patients with significant mitral regurgitation 
The prevalence of significant MR was unexpectedly high in our cohort of patients (39.5%.). The 
MRAHF study showed that secondary mitral regurgitation was the most prevalent cause in clear 
majority of patients with significant MR. It has been found a few baseline characteristics were 
different for HF patients with significant MR compared to another group of patients. Patients with 
significant MR had higher level of BNP. This might be consequence of additional myocardial stretch 
exerted by significant MR regurgitant volume leading to relative LV dilatation. It is well known that in 
chronic severe asymptomatic MR the volume overload leads to significant increase in BNP level, but 
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magnitude of increase is subtle and remains within the physiologic limits. In our cohort smaller 
degree of volume overload in already diseased hearts leads to higher intensity of BNP secretion. 
The second difference was in patients’ body habitus. The presence of more advanced HF might 
account for lower BMI in patients with significant MR. It is known that  cachexia is one of the 
symptoms of advanced HF and it predicts increased morbidity and mortality independent of 
important clinical variables such as age, ventricular function, or heart failure functional class (216). 
This is multifactorial condition with pathophysiology not completely understood (216). 
ECG changes in patients with significant MR on admission showed a tendency to a broader QRS and 
arrhythmias. In broad left bundle brunch block the electrical dyssynchrony alters closing and 
tethering forces leading to mal-coaptation of MV leaflet tips (256). It is not clear if subtle electrical 
delay causes worsening of MR in our cohort of patients or merely reflects severity of myocardial 
disease.  The association between the LA enlargement, volume related stretch of atrial wall and 
increase in LA filling pressures may be the main explanation of high prevalence of AF in this group of 
patients. At least in acute myocardial infarction this has been the main mechanism (256). 
Interestingly, those with significant MR had features of left ventricular remodelling with increase in 
end-diastolic (LVEDV) and end systolic (LVESV) volumes and reduction in LV ejection fraction (LVEF) 
in presence of significant volume overload. It is well known that LV dilatation with increased volume 
and altered chamber configuration play a key role in LV remodelling (226). It is now well established 
that altered geometry rather than closing forces could exaggerate secondary MR (159). 
Haemodynamically significant MR leads to LV remodelling through MV annular dilatation, papillary 
muscle displacement, which eventually changes the size  and shape of LV and LA. According to the 
BSE recommendations the normal cut off for LV diastolic volume is 104 ml for females and 155 ml 
for males (224). Our data did not demonstrate increase in LV  volumes above accepted threshold. All 
figures were within a normal range. However, LV diastolic and systolic volumes in HF patients with 
significant MR was considerably larger than in HF patients without volume overload. 
When MR EROA was adjusted to LV volumes (i.e. the proportionality index), we observed a rapid 
separation in survival from index admission for patients with disproportionate MR. Our study 
indicates that hearts which are disproportionately affected by MR carry a greater risk of mortality, 
suggesting MR is an active driver of poor outcome. Subject to further confirmation by other 
outcome studies, our data asserts that functional MR should be assessed and managed completely 
differently to primary MR - using adjustments including ratio/indexed parameters, rather than 
absolute volumetric analysis, to define thresholds for intervention in FMR patients. 
Patients with significant MR had more advanced pulmonary hypertension. This suggests that 
additional volume loading from MR to already raised LV filling pressures leads to more significant 
haemodynamic impact. Pulmonary hypertension develops due to congestion and pulmonary venous 
hypertension (227). Chronic congestion can lead to irreversibly elevated pulmonary vascular tone 
and pressure and as a result this process has a negative impact on patients` mortality rate (228). 
The right heart geometry and function is also altered in presence of pressure and/or volume 
overload in setting of acute heart failure (227,235,236). The right ventricular chamber is difficult for 
imaging and quantification of function due its shape and position in the chest (232). The only 
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imaging modality considered to provide comprehensive information on volume and function is MRI 
(235). This is not feasible as a bedside tool. We have therefore employed all the tricks available in 
the toolbox of echocardiography. Apart from, qualitative method assessing RV by “eyeballing”, we 
used standard TAPSE method. Tricuspid annular plane systolic excursion (TAPSE) is a widely used 
technique for assessment of RV systolic function (235,250). The M-mode cursor was placed on the 
lateral part of TV annulus in the apical four- chamber view and we traced its movement during 
systole. The level of a TV annulus excursion was used as a surrogate of RV longitudinal systolic 
function. The limitations of this method were the right ventricular load and angle dependence, and 
also, the influence of LV function (230,233). 
To overcome the limitations of TAPSE RV fractional area change (FAC) has been used to calculate RV 
longitudinal and radial function in one plane. It was obtained from four- chamber view and was 
calculated as the difference in end-diastolic area and end-systolic area and divided by end-diastolic 
area (227,235,236,250). Although this method might not fully represent the RV myocardial 
performance given the RV outflow tract is not included into the calculation in MRAHF study, the 4 
chamber view was consistently well imaged in all patients, which allowed to have reproducible data 
on RV function. 
RV FAC proved to be more sensitive and accurate method rather than TAPSE. MRAHF study showed 
that RV FAC was a powerful predictor of all-cause mortality in patients with AHF, as was systolic PA 
pressure. Moreover, RVFAC was a better prognostic marker of patients` survival rather than TAPSE. 
There is a data showing that RV FAC correlates well with MRI derived RV EF as well as predicts 
outcome in adult patients (235,236). The accurate assessment of RV function appeared to be very 
important considering our finding. 
The significant role of impaired RV in acute HF and the finding of RVFAC as a more accurate tool for 
RV contractile function assessment could be considered as a novelty presented by MRAHF study. 
It has been seen a considerable increase in 6 months mortality in patients with significant MR. 
Taking into accounts the above information the further suggestion has been made that significant 
MR is a likely contributing factor to poor patient outcome. In addition, the history of any degree of 
MR is also important factor in outcomes.  
 
4.3.2 The effect of use of National Institute for Health and Care Excellence 
(NICE) guidelines on outcome in MRAHF patients. 
The large number of acute HF patients has been identified by clinical team at the SPH. However, 
slightly more than half of the MRAHF patients did not have cardiology review within 24 hours from 
admission. This is not surprising, if a whole complexity of modern HF patients with multiple 
comorbidities would be taken into account, including non-classical presentation of HF and busy on-
call periods. 
All MRAHF patients had BNP test done as a part of the recruitment process and the test results were 
not disclosed to a clinical team. The study protocol was not designed to capture the frequency and 
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time of clinical establishment of BNP level. In general, the cardiology practice at SPH differs from the 
one suggested by NICE guidelines. BNP test is not part of clinical routine at acute admission and only 
prescribed by Cardiology team. It is therefore up to admitting team to recognise AHF symptoms and 
make timely referral to cardiology. We have used Cardiology review as equivalent of NICE BNP 
triaging. 
The cardiology review within 24 hours of admission had significant effect on outcome in patients 
with AHF. Patients who did not have cardiology review had significantly higher 6 months and 1 year 
mortality rate compared to the group which had a specialist review. This group was significantly 
older and had higher prevalence of female patient. This data correlates well with National HF Audit 
(2017-2018), which stated that the outcome is lower for those admitted to cardiology wards and for 
those who access specialist care. 
The gender gap in frequency of cardiology reviews is difficult to explain. It is known that female 
patients have different comorbidity profile: they have less prevalence of ischaemic cardiomyopathy 
as results of previous ischaemic attacks, and overall survival is better (227,244,245). They also 
present with higher prevalence of depressions (246) and, therefore, might have different complaints 
leading to  referral to other specialities. Nevertheless, it is important to study this issue further as 
lack of specialist input might delay commencement of appropriate therapy and have significant 
impact on outcome. 
There was also age difference in triaging of acute HF patients. The study showed that more elderly 
HF patients have not been seen by a specialist compared to the younger population. It is possible the 
triaging was done towards care of geriatricians. 
In summary, poor patient outcome and selection bias towards elderly and females in patients with 
no cardiology review at index AHF admission suggests that elimination of potential referral/triaging 
bias by using BNP might lead to better outcome in such patients. It demonstrates that 
NICE/European Society of Cardiology (ESC) guidelines for acute HF would achieve such objective. 
Bedside BNP which proved to be easy to use and affordable bedside tool will prevent unnecessary 
pressure on biochemistry lab if used cautiously based on well-defined protocols similar to MRAHF 
protocol. 
 
4.3.3 Economic impact of HF admissions and length of stay on the hospital 
budget 
The high expenditure of HF patients is well known fact. We wanted to know, if the significance of MR 
has any effect on HF cost increase, whether or not any other cardiac structural or functional 
abnormalities have a negative effect on the expenditure and how much a district general hospital 
like the SPH spends on HF patients.  
The current system of identifying HF without standardised laboratory approach must have 
contributed to a substantial omission of HF diagnosis amongst MRAHF patients by coding team. 
Overall, 219 MRAHF patients were not on the HF list presented by financial department. This means 
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this number of patients did not have an appropriate reimbursement for HF. The minimal cost 
implication based on our calculations is 219 x £2,255.00 (£493,845.00). The average cost of HF 
patients was grossly underestimated and the omission of large number of MRAHF patients, 
apparently, was caused by lack of universal parameter which could be used by coding team to help 
them navigate in complex discharge letters. 
Bedside BNP could be used as a clinical and triaging marker for coding team. Taking into account 
that the current cost is only £28, this test could be used routinely following the protocol established 
by our research team. This kind of approach could have led to appropriate coding, reimbursement 
and may reduce demand for echocardiography by modifying priority referral pathway for HF 
patients. 
Also, the current New York Heart Association (NYHA) classification is suboptimal since people can go 
up and down the class and HF diagnosis can be missed, whereas American College of Cardiology 
(ACC) classification could give a definitive structural non-reversible point. The ACC classification is 
much different than the NYHA functional classification system, in that there is no moving backwards 
to prior stages. For instance, with development of symptoms of stage C heart failure patients cannot 
be re-assigned to stage B. Perhaps, the combination of ACC classification and BNP test results done 
at the earliest stage of HF could provide robust coding point. 
MRAHF patients captured in Finance database had the considerably higher average cost compared 
to the cost of HF patients admitted without acute/exacerbation of chronic HF. The patients with 
isolated RVSD had higher average cost per admission compared to those with isolated LVSD. This 
phenomenon could have a few explanations given that decompensated RV is a final haemodynamic 
response in failing heart (234-236). Also, most of research is focused on LV dysfunction 
underestimating the role of RV (250,252). The literature review has showed that publication on LV 
function is nearly four times more than on RV function. 
The hospital care comprises of three-quarters of the total treatment costs for HF (195). Average 
length of hospital stay (LOS) is the main factor affecting on HF expenditure in a hospital. MRAHF 
patients had a shorter current LOS (2.3 days) compared to the data from USA (4.3 days in the 
ADHERE registry(253)) and from Europe (average 11 days in the Euro-Heart Failure Survey(16)) and 
this fact could suggests that the cost of our patients was even relatively lower than in the mentioned 
countries. However, the shorter duration of inpatient treatment maybe at the cost of a higher risk 
for early readmission (254). Unfortunately, it was not possible to follow a natural history of new AHF 
patients, the previous admissions data have been taken retrospectively and therefore not 
representative of natural history of this cohort of patients. Nevertheless, MRAHF study has 
demonstrated that patients with significant MR tend to have higher rate of HF admissions and this 
affected on cost of admissions. 
In summary, the large number of HF patients have been missed by coding team. We are not able to 
explain why this happened, however, the one of the reason could be the lack of a single marker for 
labelling HF in multiple number of comorbidities. The bedside BNP is easy to perform, not expensive 
test and could be used for clinical purposes and triaging by coding team at the same time. RV 
dysfunction has appeared to be the most expensive haemodynamic condition and more research 
attention is needed to recognise RV failure at early stages of HF. 
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4.4 Main limitations during MRAHF study 
The one of limitations in MRAHF study was a disadvantage of bedside echocardiography over 
departmental study. Due to the recruitment of acute HF patients in the whole hospital, only a 
portable machine could be used, and the time limit for a routine research echo study because of 
acuity of patients played a significant role for the quality and completeness of the study. 
Some MRAHF patients presented to the SPH clinically in a very poor condition – severely breathless, 
sitting in a chair or unable to lie flat for longer than few minutes. These circumstances, sometimes, 
were making challenging to perform a full echocardiography research study, which normally needed 
a time of 45 minutes or 1 hour. Also, some of HF patients had a very high BMI and this factor had a 
negative effect on picture quality.  
Also, as a limitation could be considered the fact that the study has been performed in a single 
district hospital in Surrey with data specific to a local area. There is a probability that if there was an 
opportunity to cover with a recruitment process a wider region of the UK or at least a bigger 
hospital, the results of our study could be different. 
The limitation of our study was that previous admissions data had been taken retrospectively and 
this approach did not allow to follow natural history of AHF patients. 
MRAHF trial was an observational study. Follow up of our HF patients is needed to find out, if 
progressive LV dilatation causes worsening of MR. 
One of limitation was a lack of financial database, it was impossible to provide exact cost of HF 
admission due to the system of reimbursement and co-morbid conditions, ambiguity of some of 
coding criteria.  
4.5 Future research 
Follow up of AHF patients needs to be done to find out effect of MR on progressive LV dilatation. 
Although data of elimination of significant secondary MR has been controversial, it is interesting to 
study, if radical management of significant MR using current structural technologies could delay 
development of right heart failure. 
4.6 Importance of MRAHF study 
1) The MRAHF study has found high prevalent of significant MR in AHF patients. The severity of MR 
and right heart failure determines the outcome in this group of patients. 
2) Bedside BNP is easy to use clinical tool which can improve patient triaging and coding. 
3) Patients with significant MR has higher costs of hospital admissions and readmission rate for HF. 
4.7 Conclusion 
MRAHF study showed the role of significant MR on patients with acute HF. The large proportion of 
HF patients had a significant MR. The significant MR proved to be causing LV remodelling, worsening 
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of LV systolic function. These HF patients had a poor prognosis with higher mortality. It has appeared 
that there is a crucial role of the right heart function. Patients with significant MR had a prominent 
systolic PAP and more impaired RV than the other group. The majority of HF patients who did not 
follow the NICE guidelines had an isolated RVSD, it was associated predominantly with significant 
MR and this population had higher mortality. The cost of HF patients with progressive RV 
dysfunction was also higher than any other category of HF population. The importance of following 
the NICE guidelines complemented by a clinical assessment has been shown in MRAHF study for 
improvement of HF patients` management and clinical outcome. The use of the bedside BNP test by 
the Research team has demonstrated a simplicity and a high effectiveness in triaging of HF patients. 
The large number of AHF patients has not been identified by the coding team, probably, due to lack 
of single marker for HF. The data, which would include a combination of bedside BNP test and 
transthoracic echocardiography  results could be indicators of HF for coding team. 
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APPENDIX 1.  
RESTING TRANSTHORACIC STUDY. Views and acquisition requirements for MRAHF study.  
1. Parasternal Long Axis view: 
- 2D loop at moderate (50-70/sec) frame rate 
- 2D loop with colour Doppler 
- 2D loop with colour tissue Doppler at high (>120/sec) frame rate 
- M-mode of aortic root/left atrium 
- M-mode of left ventricle 
- 2D loop (zoomed) of aortic root for LVOT dimension 
- 2D loop RV inflow view (optional) 
- 2D loop RV inflow view with CW Doppler for TR (optional) 
  
2. Parasternal short axis view 
- 2D loop at aortic valve level 
- PW Doppler of RVOT 
- 2D loop of MV in short axis 
- 2D loop with colour Doppler at MV level at high frame rate 
- 2D loop at papillary muscle level at moderate frame rate 
- 2D loop with colour tissue Doppler at high (>120/sec) frame rate 
- 2D loop at mid left ventricular level 
- 2D loop at apical left ventricular level 
 
3. Apical Four Chamber View 
- 2D loop at moderate frame rate focusing on all 4 chambers 
- 2D loop with colour flow Doppler on all 4 chambers 
- 2D loop zoom at moderate frame rate focusing on left and right ventricles 
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- 2D loop zoom with colour tissue Doppler at high frame rate focusing on left and right 
ventricles 
- Pulsed tissue Doppler of the lateral mitral annulus 
- Pulsed tissue Doppler of the septal mitral annulus 
- Pulsed tissue Doppler of the right ventricular free wall annulus 
- 2D loop with colour flow Doppler focusing on MR (PISA, VC, jet in LA) 
- Zoomed 2D loop with colour flow Doppler focusing on MR (PISA, VC, jet in LA) 
- 2D loop with colour flow Doppler focusing on TR 
- 2D loop at high frame rate to include both atria and pulmonary veins 
- Pulsed Doppler of the mitral inflow 
- Pulsed wave Doppler of the right upper pulmonary vein 
- Continuous wave Doppler of the MR jet 
- Pulsed Doppler of the left ventricular outflow 
- Continuous wave Doppler of aortic outflow 
- Pulsed Doppler of the tricuspid inflow 
- Continuous wave Doppler of the TR jet 
 
4. Apical Two Chamber view 
- 2D loop at moderate frame rate (LA/LV) 
- 2D loop with colour flow Doppler 
- 2D loop at moderate frame rate focusing on left ventricle 
- 2D loop with colour tissue doppler at high frame rate focusing on left ventricle 
- 2D loop zoom at high frame rate on left atrium and pulmonary veins 
- 2D loop with colour flow Doppler focusing on MR (PISA, VC and jet in LA) 
- Zoomed 2D loop with colour flow Doppler focusing on MR (PISA, VC and jet in LA) 
 
5. Apical Long Axis view 
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- 2D loop at moderate frame rate 
- 2D loop at moderate frame rate focusing on left ventricle 
- 2D loop with colour Doppler 
- 2D loop with colour flow Doppler focusing on MR (PISA, VC and jet in LA) 
- Zoomed 2D loop with colour flow Doppler focusing on MR (PISA, VC and jet in LA) 
 
6. Subcostal view 
- IVC dimension and sniff test – 2D + M-mode 
- 2D loop of Subcostal long axis view 
- 2D loop of Subcostal short axis view at papillary muscle level (optional) 




















                                            Patient Informed Consent  
  
Patient Identification Number for this study:   
  
Consent Form  
 Study Title: Incidence of significant mitral regurgitation in patients presenting with acute heart 
failure. Journey to Tertiary Centre (MRAHF).   
 Name of Researcher:                                                                                                       Please initial each box       
1. I confirm that I have read and understood the Patient Information Sheet dated 25th April 2016, 
UK version 1.1. I have had the opportunity to consider the information given concerning the MRAHF 
study and to ask questions and have had these answered satisfactorily.  
  
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving a reason. My legal rights and medical care will not be affected by my decision.  
  
3. I understand that relevant sections of my medical notes and data collected during the study may 
be looked at by individuals from the research team, from regulatory authorities or from the NHS 
Trust, where it is relevant to my taking part in this research. I agree that my data collected for the 
study will be recorded anonymously.   
  
4. I declare my agreement to archiving/storage of my data over a period of at least 5 years after 
termination of the clinical investigation. After the archiving period my data will be deleted if not 
otherwise claimed by legal, statutory or contractual regulations for record retention.  
5. I agree to take part in the MRAHF study.  
 
1 copy for patient; Original for researcher; 1 copy to be kept with hospital notes  
Name of Patient,  Date,  Signature      _________________________  ________________________           
Name of Person taking Consent (if different from Researcher),  Date,  Signature _______________ 
_________________________  ______________  ________________________________________ 




Study Title: Incidence of significant mitral regurgitation in patients presenting with acute heart 
failure. Journey to Tertiary Centre (MRAHF).    
  
Patient Information Sheet  
Dear Patient,  
We would like to ask you to take part in our clinical investigation study. Before you decide whether 
you would like to take part it is important that you understand why this research is being done and 
what it will involve. One of our team will go through this information sheet with you and answer any 
questions or concerns you may have. Please ask us if there is anything that is not clear or if you 
would like more information and talk to others if you wish. You will have to decide on the first day of 
your admission to the hospital whether you would like to take part in this study. This information 
sheet will explain the purpose of the study and what will happen to you if you take part.   
Thank you for taking the time to read this.  
Part 1  
What is the purpose of the study?  
The purpose of this study is to assess the prevalence of moderate-to-severe Mitral Regurgitation 
(MR), also known as leaky valves in patients presenting to hospital in acute Heart Failure (HF). 
Patients requiring hospital admission.  
 Why have I been invited?  
You have been asked to participate in this study because you have been admitted to hospital with 
symptoms of heart failure.   
Do I have to take part?  
Your participation in this study is completely voluntary.  You do not have to take part. Please take 
the time to read this information sheet carefully and discuss it with relatives, friends.  
It is up to you to decide whether or not to take part in this clinical study. If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent form. You will be free 
to withdraw at any time and without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive.  
If you have any questions or concerns about this study, or if you do not fully understand any part of 
it, please ask your research doctor. 
What will happen to me if I take part?  
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If you agree to take part in this clinical study you will be asked to have a recording of heart sounds 
with a special stethoscope, have a heart scan and a bedside B-type Natriuretic Peptide Blood Test 
(BNP). The level of BNP will be checked using a small device (i-STAT BNP) at the bedside. The BNP 
test results will determine your eligibility for inclusion into this study.  If your test results indicate 
elevated BNP level of (>30 pg/ml) you will undergo special procedure called Transthoracic 
Echocardiography (TTE) for grading of MR severity within 1-7 days of your hospitalisation.  A 
transthoracic echocardiogram (TTE) is the most common type of echocardiogram, which is a still or 
moving image of the internal parts of the heart using ultrasound. In this case, the probe (or 
ultrasonic transducer) is placed on the chest or abdomen of the patient to get various views of the 
heart.  
Will expenses be paid?  
We are not anticipating expenses to incur as all the investigations will be completed within current 
hospital admission.    
 What do I have to do?  
 Your participation in the study will last for the time you are in hospital.  
 You will not be eligible to participate in the study if you have other causes of breathlessness or 
palpitations.   
 What are the possible disadvantages and risks of taking part?  
Participation involves having a heart scan whilst in hospital and additional skin prick to take blood 
for BNP test.  
What are the possible benefits of taking part?  
Your participation will be important as it will help us establish whether hospital admissions with 
heart failure are caused with leaky valves. We will also be in a position to find out if assessment of 
heart sounds on auscultation is good enough to detect valvular problems as well as value of bedside 
assessment of BNP. These tests are not routinely available in current clinical settings.  
What if there is a problem?  
Any complaint about the way you have been dealt with during the study or any possible harm you 
might suffer will be addressed.  
 What will happen if I don’t want to continue in the study?  
You are free to withdraw your participation at any time with no prejudice to your standard of care. 
We will need to use the data collected on you up until the time of your withdrawal.   
What if there is a problem? If you have a concern about any aspect of this study, you should ask to 
speak to the researchers who will do their best to answer your questions. If you remain unhappy and 
wish to complain formally, you can do this by contacting Patient Advice and Liaison Service (PALS) 
within the hospital: Telephone: 01932 723553 Email: pals@asph.nhs.uk  
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Will my taking part in the study be kept confidential?  
Yes. If you consent to take part in the clinical study, any of your medical records may be inspected by 
the company sponsoring the research for purposes of analysing the results. They may also be looked 
at by people from the company and from regulatory authorities to check that the study is being 
carried out correctly. Your name, however, will not be disclosed outside the hospital. The Trust 
Information Governance Policy and Data Protection Act 1998 will be strictly followed.  
We will follow ethical and legal practice and all information which is collected about you during the 
course of the research will be kept strictly confidential. Any information about you which leaves the 
hospital/surgery will have your name and address removed so that you cannot be recognised from 
it.  
What will happen to the results of the research study?  
 After the end of this clinical study the results will be analyzed and published in medical scientific 
journals. As all information that is available from you is collected anonymously you will of course not 
be identified in any report or publication.  The study outcome will be posted on the Trust research 
and development website, which is located at: http://www.ashfordstpeters.nhs.uk/quality/research 
. Participants will be provided with the web link to access the information.  
 Who is organising and funding the study?  
 This study has been funded by Abbott Vascular Company, and sponsored by Metanoic Health Ltd.   
 Who has reviewed the study?  
 The formal review by R&D committee took place on 15.10.2015. Similar detailed review took place 
at ABBOTT Laboratories Abbott Vascular. Both panels have come to a conclusion that this is an 
innovative and interesting research project. This study will also be reviewed and approved by 
Research Ethics Committee (REC) [REC Name: North of Scotland 2].   Contact for Further Information 
Please feel free to ask any question you have about this study. If you have a concern about any 
aspect of this study, you should ask to speak to the researchers who will do their best to answer 
your questions.   
Contact Details:  
Name: Dr A. Baltabaeva  
Email: Aigul.Baltabaeva@asph.nhs.uk   
Tel No.: 01932723534 
MRAHF Study – Patient Information Sheet, Version 1.1, 25th April 2016                                              











APPENDIX 5. Baseline characteristics and observations 
 





























Mean age, years 77 80.1  79.6 78.3 81 78.2 78.3 79.3 0.393 















BMI 27.6 28.4 28.7 29.5 27.9 28.1 25.9 27.2 0.004 
BP systolic, mmHg 131 141.7 138.3 138.4 135.9 131.9 131 133 0.040 
BP diastolic, mmHg 74.8 79 74.7 76 77.2 73 73.8 75 0.555 
HR, bpm 92.1 88.8 87.3 89.9 90.5 96.4 85 88.7 0.660 
BNP, pg/ml 1902.8 1161.4 910 1124.7 1658.4 1719.9 1789 1729.1 0.0001 
Hb, g/L 125.8 118.7 121.7 123.1 122 124.5 120.4 121.6 0.492 
WBC, x10^9/l 9.66 9.72 9.03 9.79 9.49 8.21 8.61 8.3 0.062 
CRP mg/dL 29.9 23.8 33.1 28 29.6 32.8 33.3 31.9 0.363 
eGFR, mL/min/1.73m2 47.6 49.1 48.8 49.1 48.2 48.8 45.7 47.1 0.183 
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ECG, QRS duration, 
seconds 
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APPENDIX  6. Symptoms at hospital presentation 
 
 
LVEF <40% LVEF 40-
49% 
LVEF 50+ % Mild MR    Moderate 
MR 
                 
Moderate-
Severe MR 
Severe MR Significant 
MR 
 
n % n % n % n % n % n % n % n % 
Peripheral 
oedema, patients 
110 65.5% 56 57.1% 95 63.8% 166 65.6% 35 55.6% 14 58.3% 49 62.8% 98 59.4% 
Shortness of 
breath, patients 
161 95.8% 90 91.8% 147 98.7% 243 96.0% 58 92.1% 24 100.0% 75 96.2% 157 95.2% 
Palpitation, 
patients 
15 8.9% 13 13.3% 23 15.4% 32 12.6% 5 7.9% 5 20.8% 9 11.5% 19 11.5% 
Collapse, patients 3 1.8% 0 0.0% 0 0.0% 0 0.0% 1 1.6% 1 4.2% 1 1.3% 3 1.8% 
Dizzy, patients 2 1.2% 1 1.0% 6 4.0% 7 2.8% 0 0.0% 1 4.2% 1 1.3% 2 1.2% 
Chest Pain, 
patients 
5 3.0% 2 2.0% 9 6.0% 13 5.1% 0 0.0% 1 4.2% 2 2.6% 3 1.8% 
Orthopnea, 
patients 
14 8.3% 10 10.2% 10 6.7% 21 8.3% 4 6.3% 2 8.3% 7 9.0% 13 7.9% 
Oedema, patients 1 0.6% 0 0.0% 1 0.7% 1 0.4% 0 0.0% 0 0.0% 1 1.3% 1 0.6% 




9 5.4% 1 1.0% 5 3.4% 7 2.8% 5 7.9% 1 4.2% 2 2.6% 8 4.8% 
Syncope, patients 1 0.6% 0 0.0% 1 0.7% 1 0.4% 1 1.6% 0 0.0% 0 0.0% 1 0.6% 
Cough, patients 7 4.2% 5 5.1% 4 2.7% 9 3.6% 6 9.5% 1 4.2% 0 0.0% 7 4.2% 
Lethargy, 
patients 
1 0.6% 0 0.0% 0 0.0% 1 0.4% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
Fatigue, patients 0 0.0% 0 0.0% 1 0.7% 0 0.0% 0 0.0% 0 0.0% 1 1.3% 1 0.6% 
Claudication, 
patients 
0 0.0% 0 0.0% 1 0.7% 0 0.0% 1 1.6% 0 0.0% 0 0.0% 1 0.6% 
Decreased ET, 
patients 
0 0.0% 0 0.0% 1 0.7% 0 0.0% 1 1.6% 0 0.0% 0 0.0% 1 0.6% 
Central chest 
pain, patients 
0 0.0% 1 1.0% 0 0.0% 1 0.4% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
Confusion, 
patients 
1 0.6% 0 0.0% 1 0.7% 1 0.4% 0 0.0% 0 0.0% 1 1.3% 1 0.6% 
Reduced 
mobility, patients 
1 0.6% 3 3.1% 1 0.7% 1 0.4% 1 1.6% 0 0.0% 3 3.8% 4 2.4% 
RUQ pain, 
patients 











APPENDIX 7. Cause of precipitation. 
  LVEF 
<40% 














Acute Cardiomyopathy 0 1 0 1 0 0 0 0 
Acute Ischaemia 27 11 16 33 12 1 8 22 
Anaemia 1 1 1 2 0 1 0 1 
Aortic and Mitral 
Regurgitation 
0 1 0 0 0 0 1 1 
Aortic Regurgitation 0 1 0 0 0 0 1 1 
Aortic Stenosis 1 1 1 1 2 0 0 2 
Arrhythmia 22 6 17 31 4 5 6 15 
Bradyarrhythmia 1 3 6 8 0 1 1 2 
Bradycardia 1 0 0 1 0 0 0 0 
Cardiac Inflammation 0 0 1 1 0 0 0 0 
Cardiac Tamponade 0 0 2 2 0 0 0 0 
Chronic Ischaemia 9 0 7 11 3 1 1 5 
Cor Pulmonale 0 1 4 5 0 0 0 0 
Dilated Cardiomyopathy 1 0 0 0 0 0 1 1 
Drug Reaction 0 1 0 1 0 0 0 0 
Hypertension 1 1 1 2 1 0 0 1 
Hypertrophic 
Cardiomyopathy 
0 0 2 0 1 0 1 2 
Infection 1 0 1 1 0 1 0 1 
Lung Disease 0 0 2 2 0 0 0 0 
Mechanical 5 4 0 3 1 0 5 6 
Medication withdrawal 6 3 7 11 1 1 3 5 
Mitral Regurgitation 1 3 3 1 0 0 6 6 
Pericarditis 1 0 1 2 0 0 0 0 
Pulmonary oedema 0 1 0 1 0 0 0 0 
Restrictive 
Cardiomyopathy 
0 0 1 1 0 0 0 0 
Tachyarrhythmia 20 12 14 24 11 4 7 22 





1 0 1 2 0 0 0 0 
Unclear 63 41 51 99 22 6 30 63 




APPENDIX 8. Cardiology review and echocardiography timing as per NICE guidelines. 
 
LVEF <40% LVEF 40 - 
49% 




Severe MR Significant 
MR  
n % n % n % n % n % n % n % n % 
Group 1 - 
Cardiologist 
review within 24 
hours, number of 
patients 
94 56.0% 44 44.9% 57 38.3% 108 42.7% 35 55.6% 14 58.3% 39 50.0% 88 53.3% 
Group 2A - 
Cardiologist 
review later than 
24 hours, number 
of patients 
14 8.3% 6 6.1% 10 6.7% 17 6.7% 5 7.9% 1 4.2% 7 9.0% 13 7.9% 
Group 2B - Did 
not have 
cardiologist 
review, number of 
patients 
60 35.7% 48 49.0% 82 55.0% 128 50.6% 23 36.5% 9 37.5% 32 41.0% 64 38.8% 
Echocardiography 
within 48 hours, 
number of 
patients 
97 57.7% 52 53.1% 82 55.0% 145 57.3% 41 65.1% 11 45.8% 35 44.9% 87 52.7% 
Echocardiography 
later than 48 
hours, number of 
patients 
9 5.4% 5 5.1% 7 4.7% 12 4.7% 1 1.6% 4 16.7% 4 5.1% 9 5.5% 




62 36.9% 41 41.8% 60 40.3% 95 37.5% 21 33.3% 9 37.5% 39 50.0% 69 41.8% 
Previous 
echocardiography 
92 54.8% 59 60.2% 85 57.0% 144 56.9% 30 47.6% 16 66.7% 49 62.8% 95 57.6% 
No ECHO on 
current 
admission, but 
had ECHO before 









APPENDIX 9. Multivariable Cox-regression analysis results 
Table I.1: Multivariable Cox-regression analysis (Demographics and comorbidities 
variables – OS at 6 months) 
Predictive Variables 
HR for 
OS 95% CI p-value 
Significant MR 1.48 [1.01, 2.16] 0.044 
Gender – Male 1.05 [0.72, 1.54] 0.8 
Age - Continuous 1.06 [1.04, 1.09] <0.001 
BMI - Continuous 0.97 [0.94, 1,00] 0.094 
Known COPD - Yes 2.01 [1.23, 3.27] <0.001 
Known hypertension - Yes 1.24 [0.83, 1.84] 0.3 
Known CKD - Yes 2.16 [1.44, 3.24] <0.001 
Known IHD - Yes 1.08 [0.73, 1.59] 0.7 
Known diabetes - Yes 1.27 [0.84, 1.93] 0.3 
Known Cerebrovascular disease 
– Yes 
1.13 [0.69, 1.85] 0.6 
 
Table I.2: Multivariable Cox-regression analysis result (Comorbidities variables – OS at 6 
months) 
Predictive variables HR for OS 95% CI p-value 
Significant MR 1.58 [1.09, 2.30] 0.017 
Known COPD - Yes 1.85 [1.15, 2.96] 0.011 
Known Hypertension - Yes 1.28 [0.87, 1.90] 0.2 
Known CKD - Yes 2.50 [1.67, 3.74] <0.001 
Known IHD - Yes 1.04 [0.71, 1.53] 0.8 
Known Diabetes - Yes 1.00 [0.67, 1.49] >0.9 
Known Cerebrovascular disease 
– Yes 












OS 95% CI p-value 
Significant MR 1.49 1.03, 2.16 0.036 
Age - Continuous 1.07 1.04, 1.09 <0.001 
Known COPD - Yes 1.88 1.17, 3.01 0.009 








Table I.4 Multivariable Cox-regression analysis of MR defined by ERO/LVEDV > 0·14 cm2/ml 
Predictive Variables HR for OS 95% CI p-value 
ERO to LVEDV Ratio (Ratio > 
0·14cm2/ml) 
1·54 [1·02, 2·34] 0·042 
Gender - Male 1·04 [0·96, 0·72] 0·824 
Age - Continuous 1·06 [1·03, 1·09] <0·001 
BMI - Continuous 0·99 [0·96, 1·02] 0·62 
Known COPD - Yes 1·72 [1·07, 2·75] 0·024 
Known hypertension -Yes 1·21 [0·83, 1·75] 0·326 
Known CKD - Yes 1·81 [1·24, 2·63] 0·002 
Known IHD - Yes 1·20 [0·83, 1·74] 0·329 
Known diabetes - Yes 1·08 [0·71, 1·63] 0·723 









APPENDIX 10. Adjusted survival curves at 6 months – 3 scenarios 
Figure 1: Adjusted Survival curves at 6 months for Mild MR vs Significant MR.   
Scenario 1. Multivariable Cox-regression with MR as main risk factor and adjusted for all the 
















Figure 2: Adjusted Survival curves at 6 months for Mild MR vs Significant MR. 
Scenario 2. Multivariable Cox-regression with MR as main risk factor and adjusted for 
comorbidities variables only. 
 
Figure 3: Adjusted Survival curves at 6 months for Mild MR vs Significant MR 
Scenario 3. Multivariable Cox-regression with MR as main risk factor and adjusted for all the 
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